References

234

7.0 REFERENCES

Abdel Wahab N, Weston BS, Mason RM. Modulation of the TGF- β /Smad signaling pathway inmesangial cells by CTGF/CCN2.Exp Cell Res 307(2): 305-14, 2005.Abrass CK, Peterson CV, Raugi GS. Phenotypic expression of collagen types in mesangial matrix ofdiabetic and non-diabetic rats. Diabetes 37: 1695-1702, 1988.Afzal N, Ganguly PK, Dhalla KS et al. Beneficial effects of Verapamil in diabetic cardiomyopathy.Diabetes 37: 936-42, 1988.Afzal N, Pierce GN, Elimban V. Influence of Verapamil on some subcellular defects in diabeticcardiomyopathy. Am J Physiol 256: E453-E458, 1989.Agardh CD, Agardh E, Andersson A, Hultberg B. Lack of association between plasma homocysteinelevels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 54: 637-41, 1994.

Agarwal R, Saha C, Battiwala M, Vasavada N, Curley T, Chase SD, Sachs N, Semret MH. A pilotrandomized controlled trial of renal protection with pioglitazone in DN. Kidney Int 68: 285-92, 2005.

Aguilera, G. Factors controlling steroid biosynthesis in the zona glomerulosa of the adrenal. J SteroidBiochem Mol Biol 45: 147-51, 1993.Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 ininsulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action.Journal of Biological Chemistry 277: 1531-37, 2002.

Ahmad F, Azevedo JL, Cortright R, Dohm GL, Goldstein BJ. Alterations in skeletal muscleproteintyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes.Journal of Clinical Investigation 100:449-58, 1997.

Ahren B, Larsson H, Wilhelmsson C, Nasman B, Olsson T. Regulation of circulating leptin inhumans. Endocrine 7: 1-8, 1997.Ahren B, Scheurink AJ. Marked hyperleptinemia after high-fat diet associated with severe glucoseintolerance in mice. European Journal of Endocrinology 139: 461-7, 1998.Ajit Kar, Choudhary BK, Bandhopadhyay NG. Preliminary studies on the inorganic constituents ofsome indigenous hypoglycemic herbs on oral glucose tolerance test. Journal of Ethnopharmacology64: 179-184, 1999.

Akdemir O, Dağdeviren B, Altun A, Uğur B, Arikan E, Tuğrul A, Ozbay G. Quantitative ultrasonicmyocardial texture analysis of the diabetic heart. Anadolu Kardiyol Derg. 1(1): 17-21, 2001.Akimoto K, Takahashi R, Moriya S, Nishioka N, Takayanagi J, Kimura K, Fukui Y, Osada S,Mizuno K, Hirai S, Kazlauskas A, Ohno S. EGF or PDGF receptors activate atypical PKClambdathrough phosphatidylinositol 3-kinase. EMBO Journal 15: 788, 1996.

Alarcon-Aguilara FJ, Roman-Ramos R, Perez-Gutierrez S, Aguilar-Contreras A, Contreras-WeberCC, Flores-Saenz JL. Study of the anti-hyperglycemic effect of plants used as antidiabetics. Journalof Ethnopharmacology 61(2): 101-10, 1998.

Alford FP, Martin FIR, Pearson MJ. Significance and interpretation of mildly abnormal oral glucosetolerance test. Diabetalogia 7: 173-80, 1971.Alvestrand A, Mujagic M, Wajngot A, Efendic S. Glucose intolerance in uremic patients: the relativecontributions of impaired b cell function and insulin resistance. Clin Nephrol 31: 175-83, 1989.

Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int Suppl 62: S48-52,1997.American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 25 Suppl 1:S1-147, 2002.Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications:estimates and projections to the year 2010. Diabetic Med. 14: S1-S85, 1997.

References

235

Andersen AR, Christiansen JS, Andersen JK, Kreiner JK, Deckert T. Diabetic nephropathy in type 1(insulin dependent) diabetes: an epidemiological study. Diabetologia 25: 496-501, 1983.Andersen S, Jung F, Ingelfinger J. Renal RAS in diabetes. functional, immunohistochemical andmolecular biological correlations. Am J Physiol 265: F477-F86, 1993.Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of AT IIreceptor blockade in type 1 diabetic patients with DN. Kidney Int 57: 601-6, 2000.Andersen S, van Nieuwenhoven FA, Tarnow L, Rossing P, Rossing K, Wieten L, Goldschmeding R,Parving HH. Reduction of urinary CTGF by Losartan in type 1 patients with DN.Kidney Int 67(6):2325-9, 2005.

Anderson S, Jung FF, Ingelfinger JR. Renal RAS in diabetes functional, immunohistochemical, andmolecular biological correlations. Am J Physiol 265: F477-86, 1993.Andress DL, Hercz G, Kopp JB, Endres DB, Norris KC, Coburn JW. Bone histomorphometry ofrenal osteodystrophy in diabetic patients. J Bone Miner Res 2: 525-31, 1987.Anjaneyulu M, Chopra K. Diltiazem attenuates oxidative stress in diabetic rats. Ren Fail. 27(3): 335-44, 2005.

Anversa P, Leri A, Beltrami CA. Myocyte death and growth in failing heart. Lab Invest 78: 767-86,1998.Appel G, Bolton K, Freedman B. Pimagedine lowers total urinary protein and slows progression ofovert nephropathy in patietns with type 1 diabetes. J Am Soc Nephrol 10: 153A (Abstract) , 1999.Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients withdiabetes. Diabetes Care 25: 134-47, 2002.Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am, 18: 103-21,1989.Asano T, Shibasaki Y, Kasuga M, Kanazawa Y, Takaku F, Akanuma Y, Oka Y. Cloning of a rabbitbrain glucose transporter cDNA and alteration of glucose transporter mRNA during tissuedevelopment. Biochemical and Biophysical Research Communications 154: 1204-11, 1988.

Asano T, Takaku F, Oka Y. The nucleotide sequence of cDNA for a mouse liver-type glucosetransport protein. Nucleic Acids Research 17: 6386, 1989.Aso Y, Fujiwara Y, Tayama K, Takanashi K, Inukai T, Takemura Y. Relationship between plasmasoluble thrombomodulin levels and insulin resistance syndrome in type 2 diabetes: a comparisonwith von Willebrand factor. Eperimental and Clinical endocrinology & Diabetes 109: 210−16, 2001.

Astori E, Fiorina P, Contini GA et al. Isolated and Preclinical impairment of left ventricular filling ininsulin-dependent and non-insulin dependent diabetes mellitus. Clin Cardiol 20: 536-40, 1997.Atkinson M, Leiter EH. The NOD mouse model of insulin dependant diabetes mellitus as good as itgets? Nature Medicine 5: 601, 1999.Atkinson MA, Bowman MA, Campbell L. Cel!ular immunity to a determinant common to glutamatedecarboxylase and coxsackie virus in insulin dependant diabetes mellitus. Journal of ClinicalInvestigation 94: 2125, 1994.

Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositionalabnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 13: 2833-41, 1998.

Attman PO, Nyberg G, William-Olsson T, Knight-Gibson C, Alaupovic P. Dyslipoproteinemia indiabetic renal failure. Kidney Int 42: 1381-9, 1992.Augustine J, Vidt DG. The Cleveland clinic disease management project. Medicine Index, 2004.Bagdade JD, Porte D, Bierman, EL. Acute insulin withdrawal and the regulation of plasmatriglyceride removal in diabetic subjects. Diabetes 17: 127- 30, 1968.Balasa B, Krahl T, Patstone G. CD40 ligand and CD40 interactions are necessary for the initiation ofinsulitis and diabetes in nonobese diabetic mice. Journal of Immunology 159: 4620, 1997.

References

236

Balasse EO, Bier DM, Havel RJ. Early effects of antiinsulin serum on hepatic metabolism of plasmafree fatty acids in dogs. Diabetes 21: 280-4, 1972.Bandyopadhyay G, Sajan MP, Kanoh Y, Standaert ML, Quon MJ, Lea-Currie R, Sen A, Farese RV.PKC-(zeta) Mediates Insulin Effects on Glucose Transport in Cultured Preadipocyte-Derived HumanAdipocytes. Journal of Clinical Endocrinology and Metabolism 87: 716-23, 2002.

Bandyopadhyay G, Standaert ML, Galloway L, Moscat J, Farese RV. Evidence for Involvement ofProtein Kinase C and Noninvolvement of Diacylglycerol-Sensitive PKCs in Insulin- StimulatedGlucose Transport in L6 Myotubes. Endocrinology 138: 4721-31, 1997.

Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann A, Nyberg G. Early glomerulopathyis present in young, type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia36: 523-9, 1993.

Bangstad HJ, Osterby R, Rudberg S, Hartmann A, Brabrand K, Hanssen KF. Kidney function andglomerulopathy over 8 years in young patients with Type I (insulin-dependent) diabetes mellitus andmicroalbuminuria. Diabetologia 45: 253-61, 2002.

Bank N, Aynedjian HS. Role of EDRF (NO) in diabetic renal hyperfiltration. Kideny Int 43: 1306-12, 1993.Bantis C, Heering P, Aker S, Klein-Vehne, Grabensee B, Ivens K. Influence of IL-10 gene G-1082APolymorphism on progression of primary glomerulonephritis. Kidney Blood Press Res 27: 267-423,2004.

Barbour GL, Sevier BR. Letter: Adrenal responsiveness in chronic hemodialysis. N Engl J Med 290:1258, 1974.Barthel A, Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. AmericanJournal of Physiology, Endocrinology and Metabolism 285: E685-E92, 2003.Barzilay J, Warram JH, Bak M, Laffel LM, Canessa M, Krolewski AS. Predisposition tohypertension: risk factor for nephropathy and hypertension in IDDM. Kidney Int 41: 723-30, 1992.Basso LV, Havel RJ. Hepatic metabolism of free fatty acids in normal and diabetic dogs. Journal ofClinical Investigation 49: 537-41, 1970.Baumann CA, Ribon V, Kanzaki M, Thurmond DC, Mora S, Shigematsu S, Bickel PE, Pessin JE,Saltiel AR. CAP defines a second signalling pathway required for insulin-stimulated glucosetransport. Nature 407: 202-7, 2000.

Bauters CH, Lamblin N, Mc Fadden EP, Van Belle E, Millaire A, De Groote P. Influence of diabetesmellitus on heart failure risk and outcome. Cardiovascular Diabetology 2: 1, 2003.Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on anold paradigm. Diabetes 48: 1-9, 1999.Belke DD, Larsen TS, Gibbs EM & Severson DL. Altered metabolism causes cardiac dysfunction inperfused hearts from diabetic (db/db) mice. American Journal of Physiology Endocrinology andMetabolism 279: E1104−E13, 2000.

Bellermann BJ, Skorecki KL Brenner BM. Reduced glomerular AT II receptor density in earlyuntreated diabetes mellitus in the rat. Am J Physiol 247: F110-F16, 1984.

Benck U, Hackel S, Clorius JH, van der Woude FJ. Heparin treatment lowers proteinuria in DNwithout affecting the renin-angiotensin-aldosteron system (RAAS). Kidney Blood Press Res 27: 267-423, 2004.

Benjamin SM, Geiss LS, Pan L, Engelgau MM, Greenlund KJ & Center for Disease Control andPrevention (CDC). Self-reported heart disease and stroke among adults with and without diabetes-United States, 1999–2001. MMWR Morbidity and Mortality Weekly Report, 52, 1065−70, 2003.

Bennet PH. Epidemiology of type 2 diabetes mellitus. In: Diabetes Mellitus, A Fundamental andClinical Text, LeRoith D, Taylor SI, Olefsky JM, (Eds.) 2nd Edition, Lippincott Williams &Wilkins, Philadelphia, USA, pp. 544-8, 2000.

References

237

Bennett RA, Pegg AE. Alkylation of DNA in rat tissues following administration of streptozotocin.Cancer Research 41: 2786-90, 1981.Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30enhances hepatic insulin action. Nature Medicine 7: 947-53, 2001.Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R, Hanssen KF. AGEs in serum predictchanges in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism,1997, 46: 661-5.

Berg TJ, Snorgaard O, Faber J. Serum levels of advanced glycation end products are associated withleft ventricular diastolic dysfunction in patients with diabetes. Diabetes Care 22: 1186, 1999.Berg UB, Torbjornsdotter TB, Jaremko G, Thalme B. Kidney morphological changes in relation tolong term renal function and metabolic control in adolescents with IDDM. Diabetologia 41: 1047-56,1998.Berglund J, Eliasson K, Lins LE, Kaijser L, Adamson U, Lins PE et al. Autonomic neuropathy animportant feature in insulin-depentdent diabetic patients with microalbumiuria. Exp. Clin.Endocrinol. (Life Sci. Adv.) 10: 129-133, 1991.

Bergman B, Haskins K. Islet-specific T-cell clones of the NOD-mouse respond to B-granule antigen.Diabetes 43: 197, 1994.Bergstrom J. Why are dialysis patients malnourished? Am J Kidney Dis 26: 229-41, 1995.Betteridge DJ. Diabetic dyslipidemia. American Journal of Medicine (Suppl.6A) 96: 25S-31S, 1994.Bingley PJ, Bonifacio E, Gale EAM. Perspectives in diabetes. Can we really predict IDDM?Diabetes 42: 213, 1993.Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Botazzo GF, Gale EA. Prediction of IDDM inthe general: strategies based on combination of autoantibody markers. Diabetes 46: 185, 1997.Bjorbaek C, Echwald SM, Hubricht P. Genetic variants in promoters and coding regions of themuscle glycogen synthase and the insulin responsive GLUT4 genes in NIDDM. Diabetes 43: 976-83, 1995.

Bjornholm M, Kawano Y, Lehtihet M, Zierath JR. Insulin receptor substrate-1 phosphorylation andphosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulinstimulation. Diabetes 46: 524-7, 1997.

Blondel O, Bailbe D, Portha B. Relation of insulin deficiency to impaired insulin action in NIDDMadult rats given streptozotocin as neonates. Diabetes 38: 610-7, 1989.Boden G. Fatty acids and insulin resistance. Diabetes Care 19: 394-5, 1996.Boehm BO, Lustig RH. Use of somatostatin receptor ligands in obesity and diabetic complications.Best Pract Res Clin Gastroenterol 16: 493-509, 2002.Boger CA, Gotz AK, Kruger B, Hosl M, Schmitz G, Riegger GA, Kramer BK. Effect of geneticvariation on therapy with ACE-I or ARBs in dialysis patients. Eur J Med Res 10(4): 161-8, 2005.Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence ofnephropathy in insulin-dependent diabetes mellitus. N Eng J Med 330: 15-18, 1994.Bolli G, de Feo P, Compagnucci P, Cartechini MG, Angeletti G, Santeusanio F. Abnormal glucosecounterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies andimpaired glucagon and epinephrine secretion. Diabetes 32: 134-41, 1983.

Bonadonna RC, del Prato S, Bonora E, Gulli G, Solini A, DeFronzo RA. Effects ofcphysiologicalhyperinsulinemia on the intracellular metabolic partition of plasma glucose. Am J Physiol 265: 943-53, 1993.

Bonnet F, Cooper, ME. Potential influence of lipids in DN: insights from experimental data andclinical studies. Diabetes Metab 26: 254-64, 2000.Bonnier-Weir S, Trent DE, Honey RN, Weir GC. Response to neonatal islets to streptozotocin:Limited b cell regeneration and hyperglycaemia. Diabetes 30: 64-9, 1981.

References

238

Bonora E, Targher G, Alberiche M, Formentini G, Calcaterra F, Lombardi S, Marini F, Poli M,Zenari L, Raffaelli A, Perbellini S, Zenere MB, Saggiani F, Bonadonna RC, Muggeo M. Predictorsof insulin sensitivity in type 2 diabetes mellitus. Diabetic Medicine 19: 535−42, 2002.

Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type 1(insulin-dependent) diabetes mellitus. Diabetologia 28: 590-6, 1985.Borch-Johnsen K, Norgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T. Is DN an inheritedcomplication? Kidney Int 41: 719-22, 1992.Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietindeficiency occurs early in DN. Diabetes Care 24: 495-9, 2001.Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 10:891-900, 1999.Boyer JK, Shihari T, Schechtman KB, Perez JE. Prevalence of ventricular diastolic dysfunction inasymptomatic, normotensive patients with diabetes mellitus. American Journal of Cardiology 93:870−5, 2004.

Braiman L, Alt A, Kuroki T, Ohba M, Bak A, Tennenbaum T, Sampson SR. Protein Kinase CdMediates Insulin-Induced Glucose Transport in Primary Cultures of Rat Skeletal Muscle. MolecularEndocrinology 13: 2002-12, 1999.

Brenner BM, Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension andprogressive renal injury. Am J Kidney Dis 23: 171-5, 1994.Breyer MD, Bottinger E, Brosius FC, Coffman TM, Harris RC, Heilig CW, Sharma K. Mousemodels of DN. J am Soc Nephrol 16: 27-45, 2005.Brown MS, Goldstein JL. In Harrisons' Principles of Internal Medicine , eds: Isselbacher KJ,Braunwald E. McGraw Hill Inc, International Edition, pp.2068, 1994.Brown R, Walsh M, Sowers JR. Influence of sex, diabetes and ethanol on intrinsic contractileperformance of isolated rat myocardium. Basic Res Cardiol. 91: 353-60, 1996.Brownlee M, Cerami A, Vlassara H. AGEs in tissue and the biochemical basis of diabeticcomplications. N Engl J Med 318: 1315-21, 1988.Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW, Smythe GA. The effects of sympathetic nervoussystem activation and psychological stress on glucose metabolism and blood pressure in subjectswith type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35: 835-43, 1992.

Burden, AC, McNally, PG, Feehally, J and Walls, J. Increased incidence of end stage renal failuresecondary to diabetes mellitus in Asian ethnic groups in the United Kingdom. Diabet Med 9: 641-5,1992.

Buren J, Liu H, Eriksson JW. Dexamethasone impairs insulin signalling and glucose transport bydepletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B inprimary cultured rat adipocytes. European Journal of Endocrinology 146: 419-29, 2002.

Burkart V, Wang ZQ, Radons J. Mice lacking poly (ADP-ribose) polymerase gene are resistant topancreatic beta-cell destruction and diabetes development induced by streptozotocin. NatureMedicine 5: 314, 1999.

Burns KD. AT II and its receptors in the diabetic kidney. Am J Kidney Dis 36: 449-67, 2000.Bursell SE, Clermont AC, Aiello LP, Aiello LM, Schlossman DK, Feener EP. Highdose vitamin Esupplementation normalizes retinal blood flow and creatinine clearance in patients with type 1diabetes. Diabetes Care 22: 1245-51, 1999.

Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Goke B. Glucagon-likepeptide 1 improves the ability of the b-cell to sense and respond to glucose in subjects with impairedglucose tolerance. Diabetes 47: 1259-65, 1998.

Cai L, Li W, Wang G. Hyperglycaemia induced apoptosis in mouse myocardium: mitochondrial C-mediated caspase-3 activation pathway. Diabetes 51: 1938-48, 2002.

References

239

Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective.Endocrine Reviews 22: 36−52, 2001.Cam MC, Pederson RA, Brownsey RW, Mcneill JH. Long term effectiveness of oral vanadyl sulfatein STZ-diabetic rats. Diabetologia 36: 218-24, 1993.Campfield LA, Smith FJ, Bum P. Strategies and Potential Molecular Targets for Obesity Treatment.Science 280: 1383-87, 1998.Caramori, ML, Fioretto, P and Mauer, M. The need for early predictors of diabetic nephropathy risk:is AER sufficient? Diabetes 49: 1399-408, 2000.Carey JO, Azevedo JL, Morris PG, Pories WJ, Dohm GL. Okadaic acid, vanadate, and phenylarsineoxide stimulate 2-deoxyglucose transport in insulin-resistant human skeletal muscle. Diabetes 44:582-8, 1995.

Carison LA, Botinger LE. Ischaemic heart disease in relation to fasting values of plasmatriglycerides and cholesterol. Lancet 1: 805-8, 1972.Caro JF, Sinha MK, Raju SM, Itloop O , Pories WJ, Flickinger EG, Meelheim D, Dohm GL. Insulinreceptor kinase in human skeletal muscle from obese subjects with and without non-insulindependant diabetes mellitus. Journal Clinical Investigation 79: 1330-37, 1987.

Carr AA, Prisant LM, Watkins LO. Detection of hypertensive left ventricular hypertrophy.Hypertension 7: 948-54, 1985.Casteilli WP. The triglyceride issue : A view from Framingham. Am Heart J 287: 413-19, 1986.Champsaur H, Bottazzo G, Bertrams J. Virologic, immunologic and genetic factors ininsulindependant diabetes mellitus. Journal of Pediatrics 100: 15, 1982.Chang L, Adams RD, Saltiel AR. The TC10-interacting protein CIP4/2 is required for insulin-stimulated Glut4 translocation in 3T3L1 adipocytes. Proceedings of National Academy of ScienceUSA 99: 12835-40, 2002.

Charron MC, Brosius FC, Alper S, Lodish HF. A glucose transport protein expressed predominantlyin insulin-responsive tissues. Proceedings of National Academy of Science USA 86: 2535-39, 1989.

Chase PH, Glasgow AM. Juvenile diabetes mellitus and serum lipids and lipoprotein levels.American Journal of Diseases of Child 130: 1113, 1976.Chaturvedi N, Stephenson JM, Fuller JH. The relationship between smoking and microvascularcomplications in the EURODIAB IDDM Complications Study. Diabetes Care 18: 785-92, 1995.Cheetham B, Kahn CR. Insulin action and insulin signaling network. Endocrine Reviews 16(2): 117-142, 1995.Chen H, Wertheimer SJ, Lin Lin CH. protein tyrosine phosphatases PTP 1B and Syp are modulatorsof insulin-stimulated translocation of glut4 in transfected rat adipose cells. Journal of BiologcalChemistry 272: 8026, 1997.

Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S. Diabetes-induced myocardial structuralchanges: role of endothelin-1 and its receptors. Journal of Molecular and Cellular Cardiology 32:1621-29, 2000.

Cheng JT, Liu IM, Chi TC, Tzeng TF, Lu FM, Chang CJ. Plasma Glucose-Lowering Effect ofTramadol in Streptozotocin-Induced Diabetic Rats. Diabetes 50: 2815-21, 2001.Cherrington AD, Fuchs H, Stevenson RW, Williams PE, Alberti KG, Steiner KE. Effect ofepinephrine on giycogenolysis and gluconeogenesis in conscious overnight fasted dogs. AmericanJournal of Physiology 247: 137-44, 1984.

Chin M, Isono M, Isshiki K, Araki S, Sugimoto T, Guo B, Sato H, Haneda M, Kashiwagi A, Koya D.Estrogen and Raloxifene, a Selective Estrogen Receptor Modulator, Ameliorate Renal Damage indb/db Mice. Am J Pathology 166(6): 1629-36, 2005.

References

240

Chiu YW, Kuo MC, Kuo HT, Chang JM, Guh JY, Lai YH, Chen HC. Alterations of glomerular andextracellular levels of glutathione peroxidase in patients and experimental rats with DN.J Lab ClinMed 145(4):181-6, 2005.

Cho H, Mu J, Kim JK, Thorvaldsen J, Chu LQ, Crenshaw EB, Kaestner KH, Bartolomei MS,Shulman GI, Birnbaum MJ. Insulin Resistance and a Diabetes Mellitus-Like Syndrome in MiceLacking the Protein Kinase Akt2 (PKC). Science 292: 1728-31, 2001.

Choi CS, Lee FN, Youn JH. Free Fatty Acids Induce Peripheral Insulin Resistance Withoutincreasing Muscle Hexosamine Pathway. Diabetes 50: 418, 2001.Christiansen JS. Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes Care 1: 146-9, 1978.Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NODscid/scid mice: relative to contributors of CD4+ and CD8+ T- cells from diabetic versus prediabeticNOD.NON-Thy-I" donors. Diabetes 42, 44, 1993.

Christie MR. Islet cell autoantigens in type 1 diabetes. European Journal of Clinical Investigation 26:827, 1996.Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria inpatient with chronic renal disease. N Engl J Med 345: 925-26, 2001.Chua SCJ, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, Leibel RL. Phenotypes ofMouse diabetes and Rat fatty Due to Mutations in the OB (Leptin) Receptor. Science 271: 994-5,1996.Clarke CF, Eason M, Reilly A, Boyce D, Werther GA. Autonomic nerve function in adolescents withType 1 diabetes mellitus: relationship to microalbuminuria. Diabet Med 16: 550-4, 1999.Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J,Lacorte JM, Basdevant A, Bougneres P, Lebouc Y, Froguel P, Guy-Grand B. A mutation in thehuman leptin receptor gene causes obesity and pituitary dysfunction. Nature 392: 398-401, 1998.

Clerk Jd, Descamps A, Vander meersch E. Colorimetric Method for Determining Tannin. BulletinAssocaition Anciens etud. Brass, University Louvain 43: 68-76, 1947.Clodi M, Riedl M, Schmaldienst S, Vychytil A, Kotzmann H, Kaider A. Adrenal function in patientswith chronic renal failure. Am J Kidney Dis 32: 52-5, 1998.Coimbra TC, Danni FF, Blotta RM, da Periara CA, Guedes MD, Graf RG. Plants employed in thetreatment of diabetes mellitus; results of an ethnophannacological survey in Porto Alegre, Brazil.Fitoterapia 63: 320-22, 1992.

Colca JR, Dailey CF, Palazuk BJ, Hillman RM, Dinh DM, Melchior GW, et al. Pioglitazonehydrochloride inhibits cholesterol absorption and lowers plasma cholesterol concentrations incholesterol fed rats. Diabetes 40: 1669–74, 1991.

Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice.Diabetologia 14: 141-8, 1978.Condonelli G, Vigliotta G, Iavorone C. PEDJPEA-15 gene controls glucose transport and isoverexpressed in type 2 diabetes mellitus. EMBO Journal 17: 3858-66, 1997.Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental DN.Diabetologia 44: 1957-72, 2001.Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proceedings of Nutrition Society 60:349-56, 2001.

Coughlin SS, Pearle DL, Baughman KL et al. Diabetes mellitus and risk of idiopathic dilatedcardiomyopathy. The Washington DC, Dilated Cardiomyopathy Study. Ann Epidemiol 4: 67-74,1994.

References

241

Cowie, CC, Port, FK, Wolfe, RA, Savage, PJ, Moll, PP and Hawthorne, VM. Disparities in incidenceof diabetic ESRD according to race and type of diabetes. N Engl J Med 321: 1074-9, 1989.

Crisa L, Mordes JP, Rossini AA. Autoiimune diabetes mellitus in BB rat. Diabetes MetabolismReview 8: 9, 1992.Cuche JL, Prinseau J, Selz F, Ruget G, Baglin A. Plasma free, sulfo and glucuro conjugatedcatecholamines in uremic patients. Kidney Int 30: 566-72, 1986.Cumin F, Baum HP, Levens N. Leptin is cleared from the circulation primarily by the kidney. Int JObes Relat Metab Disord 20: 1120-6, 1996.Cushman SW, Wardzala LJ. Potential mechanism of insulin action on glucose transport in theisolated rat adipose cell. Apparent translocation of intracellular transport systems to the plasmamembrane. Journal of Biological Chemistry 255: 4758-62, 1980.

Czech MP, Corvera S. Signaling mechanisms that regulate glucose transport. Journal of BiologicalChemistry 274: 1865-68, 1999.Dahl-Jorgensen K, Hanssen KF, Kierulf P, Bjoro T, Sandvik L, Aagenaes O. Reduction of urinaryalbumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependentdiabetes mellitus. The Oslo Study. Acta Endocrinol Copenh 117: 19-25, 1988.

Dahlquist G, Rudberg S. The prevalence of microalbuminuria in diabetic children and adolescentsand its relation to puberty. Acta Paediatr Scand 76: 795-800, 1987.Dai S, Yuven VG, Orvig C, McNeill JH. Prevention of diabetes-induced pathology in STZ-diabeticrats by bis(malto)oxovanidium (IV). Pharmacol Commun 3(4): 311-21, 1993.Darwish R, Elias AN, Vaziri ND, Pahl M, Powers D, Stokes JD. Plasma and urinary catecholaminesand their metabolites in chronic renal failure. Arch Intern Med 144: 69-71, 1984.Das B, Tandon V, Saha N. Effect of phytochemical of Flemingia vestita (Fabaceae) on glucose 6-phosphate dehydrogenase and enzyme of gluconeogenesis in cestode (Railletina echinobothriada).Comparative Biochemistry and Physiology Part C 139: 141-46, 2004.

Davis CL, Kapuku G, Snieder H, Kumar M & Treiber FA. Insulin resistance syndrome and leftventricular mass in healthy young people. American Journal of Medical Sciences 24: 2-5, 2002.DCCT research group. The absence of a glycemic threshold for the development of long termcomplications: the perspective of the Diabetes Control and Complications Trial research group.Diabetes 45: 1289-98, 1996.

DCCT Research group. The effect of intensive treatment of diabetes on the development andprogression of long term complications in insulin-dependent diabetes mellitus. The Diabetes Controland Complications Trial Research Group (DCCT Research group). N Engl J Med 329: 977-86, 1993.

DCCT study group. Retinopathy and nephropathy in patients with type 1 diabetes four years after atrial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of DiabetesInterventions and Complications Research Group. N Engl J Med 342: 381-9, 2000.

de Haan JB, Stefanovic N, Nikolic-Paterson D, Scurr LL, Croft KD, Mori TA, Hertzog P, Kola I,Atkins RC, Tesch GH. Kidney expression of glutathione peroxidase-1 is not protective againststreptozotocin-induced DN.Am J Physiol Renal Physiol: Renal Physiology, 289: F544-F51, 2005.

de Kreutzenberg SV, Avogaro A, Tiengo A & Del Prato S: Left ventricular mass in type 2 diabetesmellitus. A study employing a simple ECG index: the Cornell voltage. Journal of EndocrinologicalInvestigation 23: 139−44, 2000.

de Murcia D. Structure and function of poly (ADP-ribose) polymerase. Molecular and CellularBiochemistry 138: 15-24, 1994.De Vriese AS, Verbeke F, Schrijvers BF, Lameire NH. Is folate a promising agent in the preventionand treatment of cardiovascular disease in patients with renal failure? Kidney Int 61: 1199-209, 2002.

References

242

Debelea D, Hanson RL, Bennet PH, Roumain J, Knowler WC, Pettitt DJ. Increasing prevalence oftype II diabetes in American Indian children. Diabetologia 41: 904, 1998.DeChatel R, Wiedmann P, Flammer J, Zeigler WH, Beretta-Piccoli C, Vetter W, Reubi FC. Sodium,renin, aldosteron, catecholamines and blood pressure in diabetes mellitus. Kidney Int 12: 412-21,1977.

Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuriareflects widespread vascular damage. The Steno hypothesis. Diabetologia 32: 219-26, 1989.Deckert T, Horowitz I, Kofoed-Enevoldsen A. Possible genetic defects in the regulation ofglycosaminoglycans in patients with DN. Diabetes 40: 764-70, 1991.Deferrari G, Ravera M, Deferrari L, Vettoretti S, Ratto E, Parodi D. Renal and CardiovascularProtection in Type 2 Diabetes Mellitus: AT II Receptor Blockers. J Am Soc Nephrol 13 Suppl 3:S224-9, 2002.

DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance inuremia. J Clin Invest 67: 563-8, 1981.DeFronzo RA, Alvestrand A. Glucose intolerance in uremia: site and mechanism. Am J Clin Nutr33: 1438-45, 1980.DeFronzo RA, Andres R, Edgar P, Walker WG. Carbohydrate metabolism in uremia: a review.Medicine (Baltimore) 52: 469-81, 1973.DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM,obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14:173, 1991.

Delaunay F, Khan A, Cintra.A, Davani B, Ling ZC, Andersson A. Pancreatic beta cells are importanttargets for the diabetogenic effects of glucocorticoids. Journal of Clinical Investigation 100: 2094-98,1997.

Deng A, Baylis C. Locally produced EDRF controls preglomerular resistance and ultrafiltration. AmJ Physiol 264: F212-F5, 1993.Denton RM, Randle RJ. Concentration of triglycerides and phospholipids in rat heart andgastronemius muscles-effect of alloxan diabetes and perfusion. Biochem J 104: 416-22, 1967.

Deray G, Izzedine H, Launay-Vacher V, Bagnis C. Kidney and glitazones Ann Endocrinol (Paris).66(2 Pt 2): 1S81-90, 2005.Dey BR, Furlanetto RW, Nissley P. Suppressor of cytokine signaling (S0CS)-3 protein interacts withthe insulin-like growth factor-I receptor. Biochemical and Biophysical Research Communications278: 38-43, 2000.

Diamant M, Lamb HJ, Smit JW, de Roos A, Heine RJ. Diabetic cardiomyopathy in uncomplicatedtype 2 diabetes is associated with the metabolic syndrome and systemic inflammation. Diabetologia,48: 1669−70, 2005.

Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non insulindependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157: 1413-18,1997.

Doggrell SA. Bradykinin B2 receptors -a target in DN. Expert Opin Ther Targets 9(2): 411-4, 2005.

Dolan V, Murphy M, Sadlier D, Lappin D, Doran P, Godson C, Martin F, O'Meara Y, Schmid H,Henger A, Kretzler M, Droguett A, Mezzano S, Brady HR. Expression of gremlin, a bonemorphogenetic protein antagonist, in human DN. Am J Kidney Dis 45(6): 1034-9, 2005.

Dollery CT, Friedman LA, Hensby CN. Circulating prostacycline may be reduced in diabetes. Lancet2(8156-8157): 1365, 1979.

References

243

Domingo JL, Llobebet JM, Gornez M, Corbella J, Keen CL. Effect of oral vanadium administrationin streptozotocin-diabetic rats has marked negative side-effect which are independent of the form ofvanadium used. Toxicol 66: 279-87, 1991.

Doria A, Onuma T, Warram JH, Krolewski AS. Synergistic effect of AT II type 1 receptor genotypeand poor glycaemic control on risk of nephropathy in IDDM. Diabetologia 40: 1293-9, 1997.

Doria A. Genetic markers of increased susceptibility to DN. Horm Res 50 Suppl 1: 6-11, 1998.

Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW. Effects of free fatty acids onglucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. Journal of ClinicalInvestigation 103: 253-9, 1999.

Dunlop M. Aldose reductase and the role of the polyol pathway in DN. Kidney Int Suppl 77: S3-12,2000.Dunn BR, Ichikawa I, Pfeffer J, Troy JL, Brenner BM. Renal and systemic hemodynamic effects ofsynthetic ANP in the anaesthetized rat. Circ Res 59: 237-46, 1986.

Dutta K, Podolin DA, Davidson MB & Davidoff AJ. Cardiomyocyte dysfunction in sucrose-fed ratsis associated with insulin resistance. Diabetes 50: 1186−92, 2001.Eidemak I, Feldt-Rasmussen B, Kanstrup IL, Nielsen SL, Schmitz O, Strandgaard S. Insulinresistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and itsassociation with aerobic work capacity. Diabetologia 38: 565-72, 1995.

Eiro M, Katoh T, Sakuma Y, Sakurai K, Suzuki H, Asahi K, Watanabe K, Watanabe T. Insulinresistance highly associates with hypertension in IgA nephropathy. Clinical Nephrology, 59: 71−8,2003.

Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. New England Journal ofMedicine 314: 1360, 1986.Ekstrand AV, Groop PH, Gronhagen-Riska C. Insulin resistance precedes microalbuminuria inpatients with insulin- dependent diabetes mellitus. Nephrol Dial Transplant 13: 3079-83, 1998.Elchebly M, Payettte P, Michaliszyn E. Increased insulin sensitivity and obesity resistance in micelacking the protein tyrosine phosphatase-13 gene. Science 283: 1544, 1999.El-Haschimi K, Lehnert H. Leptin resistance - or why leptin fails to work in obesity. Experimentaland Clinical Endocrinology and Diabetes 111: 2-7, 2003.Elsner M, Guldbakke B, tiedge M, Munday R, Lenzen S. Relative Importance of transport andalkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia 43: 1528-33, 2000.Eriksson H, Welim L, Wilhelmsen L, Larsson B, Ohlson LO, Svardsudd K, Tibblin G. Metabolicdisturbances in hypertension: results from the population study: “Men born in 1913.” J Int Med 232:389-95, 1992.

Etgen GJ, Valasek KM, Broderick CL, Miller AR. In Vivo Adenoviral Delivery of RecombinantHuman Protein Kinase C-x Stimulates Glucose Transport Activity in Rat Skeletal Muscle. Journal ofBiological Chemistry 274: 22139-42, 1999.

Evans JL, Goldfine ID, Maddux BA and Grodsky GM. Are oxidative stress-activated signalingpathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52: 1-8, 2003.Fagerudd JA, Tarnow L, Jacobsen P, Stenman S, Nielsen FS, Pettersson-Fernholm KJ.Predisposition to essential hypertension and development of DN in IDDM patients. Diabetes 47:439-44, 1998.

Fain J, Scow R, Chernick S. Effects of glucocorticoids on metabolism of adipose tissue in vitro.Journal of Biological Chemistry 238: 54-8, 1963.Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons infeeding and the agouti obesity syndrome. Nature 385: 165-8, 1997.

References

244

Fang YH, Zhang JP, Zhou SX, Zheng JF, Yu YW, Yan SG, Fan WK, Cheng YS. Relationshipbetween serum vWF and PAF in type 2 diabetic patients and DN. Di Yi Jun Yi Da Xue Xue Bao.25(6): 729-31, 2005.

Fang ZY, Prins JB & Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms and therapeuticimplications. Endocrine Reviews 25: 543−67, 2004.Fang ZY, Yuda S, Anderson V, Short L, Case C, Marwick TH. Echocardiographic detection of earlydiabetic myocardial disease. Journal of the American College of Cardiology 41: 611−7, 2003.

Fantin VR, Wang Q, Lienhard GE, Keller SR. Mice lacking insulin receptor substrate 4 exhibit milddefects in growth, reproduction, and glucose homeostasis. American journal of physiology.Endocrinology and metabolism 278(1): E127-33, 2000.

Fantus IG, Tsiani E. Multifunctional actions of vanadium compounds on insulin signaling pathways:evidence for preferential enhancement of metabolic versus mitogenic effects. Molecular and CellularBiochemistry 182: 109, 1998.

Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Tumor necrosis factor alpha is anegative regulator of resistin gene expression and secretion in 3T3-Ll adipocytes. Biochemical andBiophysical Research Communications 288: 1027-31, 2001.

Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 46:1594-1603, 2003.Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon- likepeptide-I and glucose-dependent insulin releasing polypeptide. Endocrine Reviews 16: 390-410,1995.

Felber JP, Ferrannini E, Golay A, Meyer HU, Theibaud D, Curchod R. Role of lipid oxidation inpathogenesis of insulin resistance of obesity and type I1 diabetes. Diabetes 36: 1341-50, 1987.

Feldt-Rasmussen B, Mathiesen ER, Deckert T, Giese J, Christensen NJ, Bent-Hansen L, NielsenMD. Central role for sodium in the pathogenesis of blood pressure changes independent ofangiotensin, aldosterone and catecholamine in type 1 (insulin dependent) diabetes mellitus.Diabetologia 30(8): 610-7, 1987.

Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control onprogression of incipient nephropathy in insulin-dependent diabetes. Lancet 2: 1300-4, 1986.Fernandez-Real JM, Lainez B, Vendrell J, Rigla M, Castro A, Penarroja G, Broch M, Perez A,Richart C, Engel P, Ricart W. Shedding of TNF-α receptors, blood pressure, and insulin sensitivity intype 2 diabetes mellitus. American Journal of Physiology Endocrinology and Metabolism 282:E952−E9, 2002.

Fernandez-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective:the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 42: 1367−74, 1999.Ferrannini E, De Fronzo RA. Renal handling of insulin in man. Contrib Nephrol 42: 49-53, 1984.Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, DeFronzo RA. Splanchnic and renalmetabolism of insulin in human subjects: a dose response study. Am J Physiol 244: E517-27, 1983.Ferraris JR, Domene HM, Escobar ME, Caletti MG, Ramirez JA, Rivarola MA. Hormonal profile inpubertal females with chronic renal failure: before and under haemodialysis and after renaltransplantation. Acta Endocrinol (Copenh) 115: 289-96, 1987.

Fiebeler A, Nussberger J, Rong S., Al Saadi N, Dechend R, Wellner M, Meiners S, Maser C, Jeng AY, Webb LR, Luft FC, Muller DN. Aldosterone synthase inhibitor ameloriates AT II induced organdamage. Circulation 111: 3087-94, 2005.

Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, Kajstura J. Myocyte death instreptozotocin-induced diabetes in rats angiotensin II-dependent. Laboratory Investigation 80:513−27, 2000.

References

245

Fischer R. Praktikum der pharmakognosic. Springer-verlag 3rd edition. Berlin 362, 1952.Fitchett D. Have ARBs lived up to expectations? Can J Cardiol 21(7): 569-75, 2005.Flamez D, Gilon P, Moens K, Van Breusegem A, Delmeire D, Scrocchi LA, Henquin JC, DruckerDJ, Schuit F. Altered cAMP and Ca2+ signaling in mouse pancreatic islets with GLP-1 receptor nullphenotype. Diabetes 48: 1979-86, 1999.

Flamez D, Van Breuseghem A, Scrocchi LA, Quartier E, Pipeleers D, Drucker DJ, Schuit F. Mousepancreatic b-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide1 receptor gene. Diabetes 47: 646-52, 1998.

Fliser D, Franek E, Fode P, Stefanski A, Schmitt CP, Lyons M. Subacute infusion of physiologicaldoses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 12: 933-8,1997.

Flyberg A, Frystyk J, Thorlacius-ussing O, Orskov H. Somatomedin analogue administrationprevents increase in kidney somatomedin C and initial renal growth in diabetic anduninephrectomized rats. Diabetologia 32: 261-5, 1989.

Flyberg A, Thorlacius-using O, Naeraa R, Ingerslev J, Orskov H. Kidney tissue somatomedin C andinitial renal growth in diabetic and uninephrectomized rats. Diabetologia 31: 310-4, 1988.Flyberg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetickidney disease. Diabetologia 43: 1205-23, 2000.Foggensteiner L, Murlroy S, Firth J. Management of diabetic nephropathy. J R Soc Med 94: 210-7,2001.Foote EF. Prevention and treatment of diabetic nephropathy. Am J Health Syst Pharm. 52(16): 1781-92, 1995.Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, Bassal S, El-Osta A,Long DM, Panagiotopoulos S, Jerums G, Osicka TM, Cooper ME. Modulation of Soluble Receptorfor AGEs by ACE-1 Inhibition in DN. J Am Soc Nephrol 16(8): 2363-72, 2005.

Forsblom CM, Groop PH, Ekstrand A, Groop LC. Predictive value of microalbuminuria in patientswith insulin-dependent diabetes of long duration. BMJ 305: 1051-3, 1992.Forsblom CM, Groop PH, Ekstrand A, Totterman KJ, Sane T, Saloranta C. Predictors of progressionfrom normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 21: 1932-8, 1998.

Foulis AK, Frances ND, Farquharson MA, Boylston A. Massive synchronous b cell necrosis causingtype 1 diabetes: a unique histopathological case report. Diabetologia 31: 46, 1988.Francis GS. Diabetic cardiomyopathy: fact or fiction? Heart 85: 247−8, 2001.Freudenberg K, Weinger K. The Chemistry of Flavonoid Compounds. Geissman A eds. Oxford,Pregamon Press, pp. 211, 1962.Frevert EU, Bjorbak C, Venable CL, Keller SR, Kahn BB. Targeting of Constitutively ActivePhosphoinositide 3-Kinase to GLUT4-containing Vesicles in 3T3-L1 Adipocytes. Journal ofBiological Chemistry 273: 25480-7, 1998.

Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications 15: 113-9,2001.

Frohlich ED. Potential mechanisms explaining the risk of left ventricular hypertrophy Am J Cardiol59: 91A-7A, 1987.Frustaci A, Kajstura J, Chimenti C. Myocardial cell death in human diabetes. Circulation Research:87, 1123-32, 2000.Fujisawa, T, Ikegami, H, Kawaguchi, Y, Hamada, Y, Ueda, H, Shintani, M, et al. Meta analysis ofassociation of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with DNand retinopathy. Diabetologia 41: 47-53, 1998.

References

246

Fukui M, Nakamur T, Ebihara I, Shirato I, Tomino Y, Koide H. ECM geme expssion and itsmodulation by insulin in diabetic rats. Diabetes 41: 1520-27, 1992.Fukushima M, Matsuyama F, Ueda N, Egawa K, Takemoto J, Kajimoto Y, Yonaha N, Miura T,Kaneko T, Nishi Y, Mitsui R, Fujita Y, Yamada Y, Seino Y. Effect of corosolic acid onpostchallenge plasma glucose levels. Diabetes Res Clin Pract 73: 174-7, 2006.

Fuller JH, Keen H, Jarrett RJ. Haemostatic variables associated with diabetes and its complications.BMJ 292: 964-966, 1979.Gale EAM. The discovery of type 1 diabetes. Diabetes 50: 217, 2001.Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS. Defective sarcoplasmic reticular calcium transportin diabetic cardiomyopathy. American Journal of Physiology 244: E528−E35, 1983.Garvey WT, Hardin D, Juhaszova M, Dominguez JH. Effects of diabetes on myocardial glucosetransport system in rats: implications for diabetic cardiomyopathy. American Journal of Physiology264: H837−H44, 1993.

Garvey WT, Olefsky JM, Matthaei S, Marshall S. Glucose and insulin co-regulate the glucosetransport system in primary cultured adipocytes. A new mechanism of insulin resistance. Journal ofBiological Chemistry 262: 189-97, 1987.

Garvey WT, Olefsky, Marshall S. Insulin induces progressive insulin resistance in cultured ratadipocytes. Sequential effects at receptor and multiple postreceptor sites. Diabetes 35: 258-67, 1986.

Geissman A. Modern Methods of Plant Analysis, Vol III Peach K, Tracy MV, editors. SpringerVerlang Vol.3. Berlin, Gottingen, Heidelberg, pp. 471, 1955.Geissman1 A. Morden methods of plant analysis. Peach K, Tracey MV, editors. Springer VerlangVol.3: Berlin, Gottingen, Heidelberg, pp. 473, 1955.

Gerich JE. Lilly lecture 1988. Glucose counterregulation and its impact on diabetes mellitus.Diabetes 37: 1608-17, 1988.Gerich, JE. Lilly lecture. Glucose counterregulation and its impact on diabetes mellitus. Diabetes 37:1608-17, 1988.Gherasim L, Tasca C, Havriliuc C & Vasilescu C. A morphological quantitative study of smallvessels in diabetic cardiomyopathy. Morphologie et Embryologie (Bucur) 31: 191−5, 1985.Giacomelli F, Wiener J. Primary myocardial disease in the diabetic mouse. An ultrastructural study.Laboratory Investigation 40: 460−73, 1979.Gibbs EM, Stock JL, McCoid SC. Glycemic improvement in diabetic db/db mice by overexpressionof the human insulin-regulatable glucose transporter (GLUT4). Journal of Clinical Investigation 95:1512-1518, 1995.

Giles JD, Sander GE. Diabetes mellitus and heart failure: basic mechanisms, clinical features, andtherapeutic considerations. Deedwania PC Ed. Cardiology Clinics. Pensylvania, Saunders 22(4):553-68, 2004.

Gilman AG, Rall TW, Nies AS, Tayer P. In Goodman and Gilman's The Pharmacological Basis ofTherapeutics, 10th edition, McGraw-Hill, New Delhi, India, p. 1317- 22, 2001.Gin H, Aparicio M, Potaux L, Bouchet JL, Aubertin J. Reduced albuminuria and improved insulinsensitivity after dietary protein restriction in IDDM patients. Diabetes Care 12: 369-70, 1989.Girard J. Is leptin the link between obesity and insulin resistance? Diabetes Metab 23 Suppl 3: 16-24,1997.Giroix M-H, Vesco L, Portha B. Functional and metabolic perturbations in isolated pancreatic isletsfrom the GK rat, a genetic model of noninsulin-dependent diabetes. Endocrinology 132: 815-22,1993.

References

247

Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'OnofrioF. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulindependent diabetesmellitus and hypertension. A randomized, controlled trial. Annals of Internal Medicine 126: 955-9,1997.

Goldstein BJ. Regulation of insulin action by protein-tyrosine phosphatses. In: LeRoith D, OlefskyJM, Taylor SI, (Eds.) Diabetes Mellitus a fundamental and Clinical Text. Philadelphia, Lippincott-Raven 206, 2000.

Gotz AK, Boger CA, Hirschmann C, Schmitz G, Riegger GA, Kramer BK. Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage DN. Eur J Med Res 10(4):155-60, 2005.

Gould GW, Holman GD. The glucose transporter family: structure, function, and tissue-specificexpression. Biochemical Journal 295, 329-41, 1993.Goyal RK. Hyperinsulinemia and insulin resistance in hypertension: Differential effects ofantihypertensive agents. Clin Exper Hypertension 21(1&2): 167-79, 1999.Graves PM, Reuwers M: The role of enteroviral infections in the development of IDDM. limitationsof current approaches Diabetes 46: 161, 1997.Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensivetherapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. NEngl J Med. 342: 905-12, 2000.

Griffen SC, Wang J, German MS. A Genetic Defect in b-Cell Gene Expression SegregatesIndependently From the fa Locus in the ZDF Rat. Diabetes 50: 63-8, 2001.Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, WhiteMF, Shulman GI. Free fatty acid-induced insulin resistance is associated with activation of ProteinKinase C q and alterations in the insulin signalling cascade. Diabetes 48: 1270-4. 1999.

Griffin WJ, Owen WR and Perkin JE. A Phytochemical survey of eastern Australian plants forsaponins. Planta Med. 16: 75-81, 1968.Gronbaek H, Nielsen B, Frystyk J, Flyvbjerg A, Orskov H. Effect of lanreotide on local kidney IGF-Iand renal growth in experimental diabetes in the rat. Exp Nephrol 4: 295-303, 1996.Grone EF, Walli AK, Grone HJ, Miller B, Seidel D. The role of lipids in nephrosclerosis andglomerulosclerosis. Atherosclerosis 107: 1-13, 1994.Groop PH, Elliott T, Ekstrand A, Franssila-Kallunki A, Friedman R, Viberti GC. Multiplelipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes 45: 974-9, 1996.Grover JK, Vats V, Rathi SS. Anti-hyperglycemic effects of Eugenia jambolana and Tinosporacordifolia in experimental diabetes and their effects on key metabolic enzymes involved incarbohydrate metabolism. Journal of Ethnopharmacology 73: 461-70, 2000.

Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr,Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from theAmerican Heart Association. Circulation 100(10):1134-46, 1999.

Guberski DL, Thomas VA, Shek WR. Induction of type 1 diabetes by Kilham's rat virus in diabetes-resistant BB/Wor rats. Science 254: 1010, 1991.Guida L, Celentano A, Iannuzzi R, Ferrara LA. Insulin resistance, ventricular mass and function innormoglycaemic hypertensives. Nutrition, Metabolism, and Cardiovascular Diseases 11: 306−11,2001.

Guillaume-Gentil C, Assimacopoulos-Jeannet F, Jeamenaud B. Involvement of non-esterified fattyacid oxidation in glucocorticoid-induced peripheral insulin resistance in vivo in rats. Diabetologia36: 899-906, 1993.

References

248

Gulve EA, Ren JM, Marshall BA, Gao J, Hansen PA, Holloszy JO. Glucose transport activity inskeletal muscles from transgenic mice overexpressing GLUT 1. Increased basal transport isassociated with a defective response to diverse stimuli that activate GLUT4. Journal of BiologicalChemistry 269(28): 18366-70, 1994.

Gutniak M, Orskov C, Holst JJ, Ahren- B, Efendic S. Antidiabetogenic effect of glucagons-likepeptide-1(7-36)amide in normal subjects and patients with diabetes mellitus. New England Journal ofMedicine 326: 1316-22, 1992.

Haffner SM, Lehto S, Ronnemaa T, Pyorla K, Laakso M. Mortality from coronary heart disease insubjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardialinfarction. N Engl J Med 339: 229-34, 1998.

Haffner SM, Stern MP, Michell BD, Hazuda HP, Patterson PK. Incidence of type II diabetes mellitusin Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body fatdistribution. Diabetes 39: 283, 1990.

Hales CN, Barker DJ. Type 2 (non-insulin dependant) diabetes mellitus: the thrifty genes hypothesis.Diabetologia 35: 595, 1992.Haller H, Lindscau C, Quass P. High glucose concentration increase protein kinase C. activity invascular smooth muscle cells. J Hypertrns 10: 145A, 1991.Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y, Bricharcl SM.Secretion of adiponectin and regulation of apMl gene expression in human visceral adipose tissue.Biochemical and Biophysical Research Communications 288: 1102-07, 2001.

Hamby RI, Zoneraich S, Sherman L. Diabetic Cardiomyopathy. JAMA 229: 1749-54, 1974.Hanahan D: Heritable formation of pancreatic beta-cell tumours in transgenic mice expressinginsulin /simian virus 40 oncogenes. Nature 315: 115, 1985.Hannah JS, Verdery RB, Bodkin NL, Hansen BC, Le NA, Howard BV. Changes in lipoproteinconcentrations during the development of noninsulin-dependent diabetes mellitus in obese rhesusmonkeys (Macaca mulatta). Journal of Clinical Endocrinology and Metabolism 72: 1067-72, 1991.

Hansen HP, Gaede PH, Jensen BR, Parving HH. Lack of impact of low dose acetylsalicylic acid onkidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care 23: 1742-5, 2000.

Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction onprognosis in patients with DN. Kidney Int 62: 220-8, 2002.Hansen PA, Han DH, Marshall BA, Nolte LA, Chen MM, Mueckler M, Holloszy JO. A High FatDiet Impairs Stimulation of Glucose Transport in Muscle. Functional evaluation of potentialmechanisms. Journal of Biological Chemistry 273: 26157-63, 1998.

Hansen PM, Chowdhury T, Deckert T, Hellgren A, Bain SC, Pociot F. Genetic variation of theheparan sulfate proteoglycan gene (perlecan gene). Association with urinary albumin excretion inIDDM patients. Diabetes 46: 1658-9, 1997.

Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression.Annual Review of Biochemistry 66: 581-611, 1997.Harborne JB. Phytochemical Methods, a guide to modern techniques of plant analysis. 2nd edition.London, Champan & Hall Ltd., pp. 42, 1984.Hartner A, Porst M, Cordasic N, Veelken R, Klanke B, Hilgers KF. Role of the alpha 8 integrinchain in diabetic glomerular disease. Kidney Blood Press Res 27: 267-423, 2004.Haskins K, Wegmam D. Diabetogenic T-cell Clones. Diabetes 45: 1299, 1996.Hasslacher C, Ritz E, Tepstra J, Gaalasch G, Krowleski G, Rall C. Natural history of nephropathy intype 1 diabetes: relationship to metabolic control and blood pressure. Hypertension 7 (suppl II): 74-8,1985a.

References

249

Hasslacher C, Sted W, Wahl P, Ritz E. Blood pressure and metabolic control as risk factors fornephropathy in type I (insulin-dependent) diabetes. Diabetologia 28: 6-11, 1985b.Hattersley AT, Beards F, Ballantyne E, Appleton M, Harvey R, Ellard S. Mutation of theglucokinase genes of the fetus results in reduced birth weight. Nature Genetics 19: 268, 1998.Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, Haller H, Mischak H.Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int.67(6): 2313-20, 2005.

Haugen F, Jorgensen A, Drevon CA, Trayhurn P. Inhibition by insulin of resistin gene expression in3T3-L1 adipocytes. FEBS Letters 507: 105-8, 2001.Hausdorff SF, Fingar DC, Morioka K, Garza LA, Whiteman EL, Summers SA, Birnbaum MJ.Identification of Wortmannin-sensitive Targets in 3T3-L1 Adipocytes. Dissociation of insulin-stimulated glucose uptake and GLUT 4 translocation. Journal of Biological Chemistry 274: 24677-84, 1999.Hawkins M, Angelov I, Liu R, Barzilai N, Rcssetti L: The Tissue Concentration of UDP-Nacetylglucosamine Modulates the Stimulatory Effect of Insulin on Skeletal Muscle GlucoseUptake. Journal of Biological Chemistry 272: 4889-95, 1997a.

Hawkins M, Barzilai N, Chen W, Aagelov I, Hu M, Cohen P. Increased hexosamine availabilitysimilarly impairs the action of insulin and IGF-I on glucose disposal. Diabetes 45: 1734-43, 1996.Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rossetti L. Role of the Glucosamine Pathway in Fat-induced Insulin Resistance. Journal of Clinical Investigation 99: 2173-82, 1997.Hayashi T, Maruyama H, Kasai R, Hattori K, Takasuga S, Hazeki O, Yamasaki, K. Tanaka T.Ellagitannins from Lagerstroemia speciosa as activators of glucose transport in fat cells. Planta Med.68: 173-5, 2002.

Heaton A, Johnston DG, Haigh JW, Ward MK, Alberti KG, Kerr DN. Twenty four hour hormonaland metabolic profiles in uraemic patients before and during treatment with continuous ambulatoryperitoneal dialysis. Clin Sci (Lond), 69: 449-57, 1985.

Hediger MA, Coady MJ, Ikeda TS, Wright EM. Expression cloning and cDNA sequencing of theNa+/glucose transporter. Nature 330: 379-81, 1987.Hedo JA, Kahn CR, Hayashi M. Biosynthesis and glycosylation of insulin receptor. Evidence for asingle polypeptide precursor of two major subunits. Journal of Biological Chemistry 258 (16):10020, 1983.

Heesom AE, Hibberd ML, Millward A, Demaine AG. Polymorphism in the 5'-end of the aldosereductase gene is strongly associated with the development of DN in type I diabetes. Diabetes 46:287-91, 1997.

Heffetz D, Zick Y. Receptor aggregation is necessary for activation of the soluble insulin receptorkinase. Journal of Biological Chemistry 261: 889-94, 1986.Herold KC, Veyz V, Koons A. CD28/B7 costimulation regulates autoimmune diabetes induced withmultiple low doses of streptozotocin. Journal of Immunology 158: 984, 1997.Heyne N, Brenner S, Rall M, Benohr P, Grenz A, Risler T, Beischer W, Osswald H. Adenosinereuptake inhibition corrects glomerular hyperfiltration and microalbuminuria in incipient type 1 DN.Kidney Blood Press Res 27:267-423, 2004.

Hintz KK, Ren J. Prediabetic insulin resistance is not permissive to the development of cardiacresistance to insulin-like growth factor I in ventricular myocytes. Diabetes Research and ClinicalPractice 5: 89−98, 2002.

Hirayama H, Sugano M, Abe N, Yonemoch H & Makino N. Troglitazone, an antidiabetic drug,improves left ventricular mass and diastolic function in normotensive diabetic patients. InternationalJournal of Cardiology 77: 75−9, 2001.

References

250

Hirose K, Osterby R, Nozawa M, Gunderson HJG. Development of glomerular lesions inexperimental long term diabetes in the rat. Kidney Int 21: 689-95, 1982.

Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Teoman Uysal K, Maeda K, Karin M, HofamisiligilG. A central role for JNK in obesity and insulin resistance. Nature 420: 333-6, 2002.Hofteizer B, Carpenter AM. Comparison of STZ induced diabetes in rats, including volumetricquantization of pancreatic islet cells. Diabetologia. 9: 178-84, 1973.Hohenstein B, Hauskenecht B, Brekken R, Boehmer K, Riess R, Hugo C. Differential regulation ofVEGF, VEGF-R2 and VEGF-mediated VEGF-receptor activation during type 2 DN. Kidney BloodPress Res 27: 267-423, 2004.

Holman GD, Kasuga M. From receptor to transporter: insulin signaling to glucose transport.Diabetologia 40: 991-1003, 1997.Hong T, Zhao G, Gao W, Huo Y & Zhu G. Insulin sensitivity and the diffuseness of coronary arterydisease in humans. Clinical Medical Journal (England) 115: 1886-8, 2002.Hopfer U, Hopfer A, Jablonski K, Stahl RAK, Wolf G. High glucose upregulates type VIII collagen:implication for DN. Kidney Blood Press Res 27: 267-423, 2004.Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation andprogression of diabetic and other glomerulopathies. Am J Med 72: 375-80, 1982.Hostetter, TH, Rennke, HG and Brenner, BM. The case for intrarenal hypertension in the ini-tiationand progression of diabetic and other glomerulopathies. Am J Med 72: 375-80, 1982.Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissueexpression of tumor necrosis factor a in human obesity and insulin resistance. J Clin Invest 95: 2409-15, 1995.

Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance. Science 259: 97, 1993.Hotta M, Tashiro F, Ikegami H. Pancreatic beta cell-specific suppression of thioredoxin, anantioxidative and antiapoptotic protein prevents autoimmune and streptozotocin-induced diabetes.Journal of Experimental Medicine 188: 1445, 1998.

Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy.Kidney Int 59: 702-9, 2001.Hresko RC, Heimberg H, Chi MMY, Mueckler M. Insulin resistance. Journal of BiologicalChemistry 273: 20658, 1998.Hsu CC, Kao WH, Coresh J, Pankow JS, Marsh-Manzi J, Boerwinkle E, Bray MS. Apolipoprotein Eand progression of chronic kidney disease. JAMA. 293 (23): 2892-9, 2005.Huang JS, Chuang LY, Guh JY, Chen CJ, Yang YL, Chiang TA, Hung MY, Liao TN. Effect of NO-cGMP-Dependent Protein Kinase Activation on AGEs-Induced Proliferation in Renal Fibroblasts. JAm Soc Nephrol 16: 2318-29, 2005.

Huang Y, Ishizuka T, Miura A, Kajita K, Ishizawa M, Kimura M. Effect of 1a, 25-dihydroxy vitaminD3 and vitamin E on insulin-induced glucose uptake in rat adipocytes. Diabetes Res Clin Pract 55:175-83, 2002.

Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension inrats. Hypertension 10: 512-6, 1987.Hyoty H, Hiltunen M, Reunanen A. Decline of mumps antibodies in type (insulindependant) diabeticchildren and a plateau in the rising incidence of type 1 diabetes after introduction of mumps-measlesrubella vaccine in Finland: Childhood Diabetes in Finland Study Group. Diabetologia 36:1303, 1993.

References

251

Iimura O, Shimamoto K, Matsuda K, Masuda A, Takizawa H, Higashiura K, Miyazaki Y, Hirata A,Ura N, Nakagawa M. Effects of angiotensin receptor antagonist and angiotensin converting enzymeinhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives.American Journal of Hypertension 8: 353-7, 1995.

Ikegami H, Makino S, Yamato E. Identification of new susceptibility locus for insulin-dependantdiabetes mellitus by ancestral halotype congenic mapping. Journal of Clinical Investigation 96: 1936,1995.

Itoh N, Hanafusa T, Miyazaki A. Mononuclear cell infiltration and its relation to expression of majorhistocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens fromnewly diagnosed insulin-dependant diabetes mellitus patients. Journal of Clinical Investigation 92:213, 1993.Ivorra MD, Paya M, Villar A. A review of natural products and plants as potential anti-diabeticdrugs. Journal of Ethnopharmacology 27: 243-75, 1989.

Ivorra MD, Paya M, Villar A. Hypoglycemic and insulin release effect of tormentic acid: a newhypoglycemic natural product. Planta Medica 54: 282-6, 1988.Iwai-Kanai E, Hasegawa K, Araki M, Kakita T, Morimoto T, Sasayama S. α- and ß-adrenergicpathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation 100:305−11, 1999.

Iwamoto M, Mizuiri S, Arita M, Hemmi H. Nuclear factor-kappaB activation in diabetic rat kidney.evidence for involvement of P-selectin in DN. Tohoku J Exp Med 206(2):163-71, 2005.Jacobsen P, Rossing K, Tarnow L, Rossing P, Mallet C, Poirier O. Progression of DN innormotensive type 1 diabetic patients. Kidney Int Suppl 71: S101-5, 1999.Jaeneisch R: Transgenic animals. Science 240: 1468, 1988.Jafri MA, Aslam M, Javed K, Singh S. Effect of Punica granatum Linn. (flowers) on blood glucoselevel in normal and alloxan-induced diabetic rats. Journal of Ethnopharmacology 70: 309-14, 2000.

Janssen JA, Jacobs ML, Derkx FH, Weber RF, van der Lely AJ, Lamberts SW. Free and total IGF-I,IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabeticretinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin EndocrinolMetab 82: 2809-15, 1997.

Jansson PA, Eliasson B, Lindmark S, Eriksson JW. Endocrine abnormalities in healthy first degreerelatives of type 2 diabetes patients potential role of steroid hormones and leptin in the developmentof insulin resistance. Eur J Clin Invest 32: 172-8, 2002.

Jaysooriya AP, Sakono M, Yakizaki C, Kawano M, Yamamoto K, Fukuda N. Effects of Momordicacharantia powder on serum glucose levels and various lipid parameters in rats fed with cholesteroland cholesterol-enriched diets. Journal of Ethnopharmacology 72: 331-6, 2000.

Jenkins DJA, Josse RG. Effect of reduced carbohydrate absorption on carbohydrate and lipidmetabolism. European Journal of Clinical Nutrition 49 (Suppl. 3): s63-s8, 1995.Jensen T, Richter EA, Feldt-Rasmussen B, Kelbaek H, Deckert T. Impaired aerobic work capacity ininsulin dependent diabetics with increased urinary albumin excretion. BMJ (Clin Res Ed 296: 1352-4), 1988.

Jiang T, Sweeney G, Rudolf MT, Klip A, Traynor-Kaplan A, Tsien RY. Membrane-permeant EstersPhosphatidylinositol 3,4,5-Trisphosphate. Journal of Biological Chemistry 273: 11017-24, 1998.

Johnson BF, Nesto RW, Pfeifer MA, Slater WR, Vinik AI, Chyun DA, Law G, Wackers FJ & YoungLH. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitoradministration. Diabetes Care 27: 448-54, 2004.

References

252

Judd AM, Call GB, Barney M, Mcllmoil CJ, Balls AG, Adams A, Oliveira GK. Possible function ofIL-6 and TNF as intra-adrenal factors in the regulation of adrenal steroid secretion. Annals of NewYork Academy of Science 917: 628-37, 2000.

Judy WV, Hari SP, Stogsdill WW, Judy JS, Naguib YM. Passwater R. Antidiabetic activity of astandardized extract (Glucosol) from Lagerstroemia speciosa leaves in Type II diabetics A dose-dependence study. Journal of Ethnopharmacology 87(1): 115-7, 2003.

Jungmann E, Felber A, Graeber S, Hillmann U, Haak T, Palitzsch K, Usadel K. Human ANP inpatients with type 1 diabetes mellitus: is it related to be development of DN. Clin Invest 71: 604-9,1993.

Juntti-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Vignati L, Efendic S. Theantidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improvesdiabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 19: 1200-6, 1996.

Kahn BB: Shulman GI. DeFronzo RA, Cushman SW. Rosseiti L. NormaIization of blood glucose indiabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cellswithout restoring glucose transporter gene expression. Journal of Clinical Investigation 87: 561-70,1991.

Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolicparameters and arterial stiffness in hypertensive type 2 diabetic patients. Journal Hypertension 24:1397−403, 2006.

Kakuda T, Sakane I, Takihara T, Ozaki Y, Takeuchi H. Hypoglycemic effect of extracts fromLagerstroemia speciosa L. leaves in genetically diabetic KK-AY mice. Biosci BiotechnolBiochem.60(2): 204-8, 1996.

Kamper AL, Nielsen OJ. Effect of enalapril on haemoglobin and serum erythropoietin in patientswith chronic nephropathy. Scand J Clin Lab Invest 50: 611-8, 1990.Kannel WB, Gorden T, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk ofcoronary heart disease:Framingham study. Ann Int Med 72: 813-22, 1974.Kannel WB, Gorden T. Left Ventricular hypertrophy by electrocardiogram: prevalence, incidenceand mortality in the Framingham study. Ann Int Med 71: 89-105, 1969.Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease:the Framingham study. Diabetes Care. 2: 120-6, 1979.Kannel WB. Metabolic risk factors for coronary heart disease in women . Perspective from theFramingham study. Am Heart J 114: 413-9, 1987.Kaprio J, Tuomilehto J, Koshenvuo M. Concordance for type 1 (insulin dependant) and type 2(insulin independent) diabetes mellitus in a population-based cohort of twins in Finland.Diabetologia 35: 1070, 1993.

Karger AG, Basel. Zhu B, Shen H, Zhou J, Lin F, Hu Y. Effects of Simvastatin on Oxidative Stressin Streptozotocin-Induced Diabetic Rats: A Role for Glomeruli Protection.Nephron Exp Nephrol.101(1): e1-e8, 2005.

Karvonen M, Tuomilehto J, Libman I. A review of the recent epidemiological data on the worldwideincidence of type I (insulin-dependant) diabetes mellitus. Diabetologia 36: 883, 1993.Kasim-Karakas SE, Vriend H, Almario R, Chow LC, Goodman MN. Effects of dietarycarbohydrates on glucose and lipid metabolism in golden Syrian hamsters. Journal of Laboratory andClinical Medicine 128: 208-13, 1996.

Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF. Renal injury of diet inducedhypercholesterolemia in rats. Kidney Int 37: 880-91, 1990.

Katagiri H, Asano T, Ishihara H. Overexpression of the catalytic alpha of phosphatidylinositol 3-Kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1adipocytes. Journa1 of Biological Chemistry 271: 16987-90, 1996.

References

253

Kawaguchi M, Techigawara M, Ischiata T. A comparison of ultra structural changes onendomyocardial biopsy specimens obtained from patients with diabetes mellitus with and withouthypertension. Heart Vessels 12: 267-74, 1997.

Kawano Y, Rincon J, Soler A, Ryder JW, Nolte LA, Zierath JR. Changes in glucose transport andProtein kinase Cbeta(2) in rat skeletal muscle induced by hyperglycaemia. Diabetologia 42: 1071-9,1999.

Kayano T, Burant CF, Fukumoto H, Gould GW, Fan YS, Eddy RL, Byers MG, Shows TB, Seino S,Bell GI. Human facilitative glucose transporters: isolation, functional characterization, and genelocalization of cDNAs encoding an isoform (GLUTS) expressed in small intestine, kidney, muscle,adipose tissue and an unusual glucose transporter pseudogene-like sequence (GLUT6). Journal ofBiological Chemistry 265: 3276-82, 1990.

Kelly DJ, Chanty A, Gow RM, Zhang Y, Gilbert RE. Protein Kinase C{beta} Inhibition AttenuatesAttenuates Osteopontin Expression, Macrophage Recruitment, and Tubulointerstitial Injury inAdvanced Experimental DN.J Am Soc Nephrol 16(6): 1654-60, 2005.

Khoursheed M, Miles PD, Gao M, Lee MK, Moossa AR, Olefsky JM. Metabolic effects oftroglitazone on fat-induced insulin resistance in the rat. Metabolism 38: 1489-94, 1995.

Kieffer TJ, Habener JF. The glucagons-like peptides. Endocrine Reviews 20 (6): 876-913, 1999.

Kieffer TJ, McIntosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropicpolypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.Endocrinology 136: 3585-96, 1995.

Kikkawa R, Kitamura E, Fujiwara Y, Arimura T, Haneda MYS. Impaired contractile responsivenessof diabetic g lomeruli to AT II: a possible indication of mesangial dysfunction in diabetes mellitus.Biochem Biophys Res Commun 136: 1185-90, 1986.

Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Hyodo N, Shigenobu S, Miura S.Mizoribine reduces renal injury and macrophage infiltration in non-insulin dependent diabetic rats.Nephrology Dialysis Transplantation 20(8): 1573-81, 2005.

Kim ST, Moley KH. The expression of GLUT8, GLUT9a and GLUT9b in mouse testis and sperm.Reprod Sci. 14(5): 445-55, 2007.Kino M, Yamato T, Aomine M. Simultaneous measurement of NO, blood glucose and monoaminesin the hippocampus of diabetic drat: as in vivo microdialysis study. Neurochem Int 44(2): 65-73,2004.

Kitayama S, Abe M, Negishi K, Takahashi K, Ishii J, Komeda K. Reciprocal changes in leftventricular collagen-1 chain gene expression between type I and IV in spontaneously diabetic rats.Diabetes Res Clin Pract. 26:163-9, 1994.

Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 318: 1657-66,1988.Klanke B, Codasic N, Hartner A, Veelken R, Hilgers KF. Statin treatment reduces glomerulusinflammation and injury in hypertensive nephrosclerosis. Kidney Blood Press Res 27: 267-423,2004.Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ. Prevalence of diabeticcomplications in relation to risk factors. Diabetes 35: 1332-9, 1986.Kohn AD, Kovacina KS, Roth RA. Insulin stimulates the kinase activity of RAC-PK, a pleckstrinhomology domain containing ser/thr kinase. EMBO Journal 14: 4288-95, 1995.Kohn AD, Takeuchi F, Roth RA. Akt, a Pleckstrin Homology Domain Containing Kinase, isActivated Primarily by Phosphorylation. Journal of Biological Chemistry 271: 21920, 1996.Koj A. Initiation of acute phase response and synthesis of cytokines. Biochem Biophys Acta 10: 709-20, 1996.

References

254

Kolb H, Kroncke KD. IDDM. lesson from low dose streptozotocin model in mice. Diabetes Review1: 116, 1993.Kolb H. Benign versus destructive insulitis. Diabetes Metabolism Reviews 13: 139, 1997.Kordonouri O, Danne T, Enders I, Weber B. Does the long term clinical course of type I diabetesmellitus differ in patients with prepubertal and pubertal onset? Results of the Berlin RetinopathyStudy. Eur J Pediatr 157: 202-7, 1998.

Kraegen EW, James DE, Storlien LW, Burleigh KM, Chisholm DJ. In vivo insulin resistance inindividual peripheral tissues of the high fat fed rat: assessment by euglycaemic clamp plusdeoxyglucose administration. Diabetologia 29: 192-8, 1986.

Krishna KM, Gopal GS, Chalam CR, Madan K, Kumar VK, Prakash GJ, Annapurna A. Theinfluence of sulindac on diabetic cardiomyopathy: a non-invasive evaluation by Dopplerechocardiography in streptozotocin-induced diabetic rats. Vascular Pharmacology 43: 91−100, 2005.

Kriska AM, LaPorte RE, Pettitt DJ. The association of physical activity with obesity, fat distributionand glucose intolerance in Pima Indians. Diabetologia 36: 863, 1993.Kriz W, Gretz N, Hahnel B, Podlich D, Hoffmann S. Glomerulosclerosis and albuminuria intransgenic rats due to AT1 receptor over expression in podocytes. Kidney Blood Press Res 27: 267-423, 2004.Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH. Glycosylated hemoglobin and therisk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 332:1251-5, 1995.

Krook A, Roth RA, Jiang XJ, Zierath JR, Wallberg-Henriksson H. Insulin-stimulated Akt kinaseactivity is reduced in skeletal muscle from NIDDM subjects. Diabetes 47:- 1281-1286, 1998.Kuhlmann A, Campean V, Haas CS, Gross ML, Reulbach U, Hartner A, Aigner T, Amann K.Glomerular collagen 4 expression in experimental type 1 and 2 diabetes and human diabetic andhypertensive nephropathy. Kidney Blood Press Res 27: 267-423, 2004.

Kulas DT, Goldstein BJ, Mooney RA. The transmembrane protein tyrosine phosphatase LARmodulates signaling by multiple receptor tyrosine kinases. Journal of Biological Chemistry 217:748, 1996.

Kullin M. K (ATP) channel openers protect rat islets against the toxic effect of streptozotocin.Diabetes 49: 1131-36, 2000.Laitinen T, Vauhkonen IK, Niskanen LK, Hartikainen JE, Lansimies EA, Uusitupa MI. Powerspectral analysis of heart rate variability during hyperinsulinemia in nondiabetic off spring of type 2diabetic patients: evidence for possible early autonomic dysfunction in insulin-resistant subjects.Diabetes 48: 1295-9, 1999.

Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol lowering therapy may retard the progression ofDN. Diabetologia 38: 604-9, 1995.Lammers R, Bossenmaier B,Cool DE. Differential activities of protein tyrosine phosphatase in intactcells. Journal of Biological Chemistry 268: 22456, 1993.Lampeter EF, Klinghammer A, Scherbaum W. The Deutsche Nicotinamide intervention Study: anattempt to prevent type I diabetes DENIS Group. Diabetes 47: 980, 1998.Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucosedisposal and hepatic glucose output. Endocrinology 130: 43, 1992.LaPorte RE, Dorman JS, Tajima N, Cruickshanks KJ, Orchard TJ, Cavender DE. Pittsburgh Insulin-Dependent Diabetes Mellitus Morbidity and Mortality Study: physical activity and diabeticcomplications. Pediatrics 78: 1027-33, 1986.

Lappin DW, Hensey C, McMahon R, Godson C, Brady HR. Gremlins, glomeruli and DN. Curr OpinNephrol Hypertens 9: 469-72, 2000.

References

255

Le Lay S, Boucher J, Rey A, Castan-Laurel1 I, Krief S, Ferre P. Decreased resistin expression inmice with different sensitivities to a high-fat diet. Biochemical and Biophysical ResearchCommunications 289: 564-7, 2001.

Lebovitz HE, Pasmantier R. Combination insulinsulphonylurea therapy. Diabetes Care 13; 667-75,1990.

Lee MK, Miles PD, Khoursheed M, Geo KM, Moossa AR, Olefsky JM. Metabolic effects oftroglitazone on fructose-induced insulin resistance in the rat. Diabetes 43: 1435-9, 1994.Leehey DJ, Singh AK, Alavi N, Singh R. Role of AT II in DN. Kidney Int Suppl 77: S93-8, 2000.Leslie RD, Taylor R, Pozzilli P. The role of insulin resistance in the natural history of type 1diabetes. Diabet Med 14: 327-31, 1997.

Leturque A, Loizeau M, Vaulont S, Salminen M, Girard J. Improvement of insulin action in diabetictransgenic mice selectively overexpressing GLUT4 in skeletal muscle. Diabetes 45: 23-7, 1996.Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D. Left ventricular mass indexincrease in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34: 125-34, 1999.Levin ME, Boisseau VC, Avioli LV. Effects of diabetes mellitus on bone mass in juvenile and adultonset diabetes. N Engl J Med 294: 241-5, 1976.Lewinter MM. Diabetic Cardiomyopathy. an overview. Coronary artery disease 7: 95-8, 1996.Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB. Renoprotective effect of theangiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. NEngl J Med 345: 851-60, 2001.

Lewis JF, DaCosta M, Wargowich T & Stacpoole P. Effects of dichloroacetate in patients withcongestive heart failure. Clinical Cardiology 21: 888-9, 1998.Li J, Yu X, Pan W, Unger RH. Gene expression profile of rat adipose tissue at the onset of high-fatdiet obesity. American Journal of Physiology, Endocrinology and Metabolism 282: E1334-E41,2002.Liedtke AJ, DeMaison L, Eggleston AM, Cohen LM, Nellis SH. Changes in substrate metabolismand effects of excess fatty acids in reperfused myocardium. Circ Res 62: 535-42, 1988.Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis. New model of diabetes mellitus.Science 193: 415, 1976.Lind L, Berne C, Anden B, Lithell H. Relationship between diastolic hypertension and myocardialmorphology and function in elderly males with diabetes mellitus. Diabetologia 39: 1603-6, 1996.Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S,Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O. Nieminen MS. Omvik P, Oparil S, Wedel H,Aurup P, Edelman J, Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes inthe Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trialagainst atenolol. Lancet 359: 1004-10, 2002.

Lindmark S, Wiklund U, Bjerle P, Eriksson JW. Does the autonomic nervous system play a role inthe development of insulin resistance? A study on heart rate variability in first degree relatives oftype 2 diabetes patients and control subjects. Diabet. Med 20(5): 399-405, 2003.

List PH, Horhammer L. Hager Hand buch der pharmazeutischem praxis. Berlin, Springer VerlagBand 1, pp. 447, 1967.Lithell HO, McKeigue PM, Berglund L, Mohsen R. Lithell UB, Leon DA. Relations of size at birthto non-insulin dependant diabetes mellitus and insulin concentrations in men aged 50-60 years. BMJ312: 406, 1996.

Liu IM, Hsu FL, Chen CF, Cheng JT. Antihyperglycemic action of isoferulic acid in streptozotocin-induced diabetic rats. British Journal of Pharmacology 129:631-6, 2000.

References

256

Liu DT, Adamson UC, Lins PE, Kollind ME, Moberg EA, Andreasson K. Inhibitory effect ofcirculating insulin on glucagon secretion during hypoglycemia in type I diabetic patients. DiabetesCare 15: 59-65, 1992.

Liu FJ, Kim Y, Li X, Liu J, Li X, Chen. An extract of Lagerstroemia speciosa L. has insulin-likeglucose uptake-stimulatory and adipocyte differentiation-inhibitory activities in 3T3-L1 cells. J.Nutr. 131, 2242-7, 2001.

Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, Meggs LG, Malhotra A.Glycation endproduct cross-link breaker reduces collagen and improves cardiac function in agingdiabetic heart. American Journal of Physiology Heart Circulatory Physiology 285: H2587−H91,2003.Liu X, Kim J, Li Y, Li J, Liu F, Chen X. Tannic acid stimulates glucose transport and inhibitsadipocyte differentiation in 3T3-L1 Cells. J. Nut. 135: 165-71, 2005.Lo GP, Careddu A, Magni G, Quagliata T, Pacifici L & Carminati P: Autonomic neuropathy instreptozotocin diabetic rats: effect of acetyl-L-carnitine. Diabetes Research and Clinical Practice 56:173−80, 2002.

Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B. Effects of vitamin E on cardiovascular andmicrovascular outcomes in high risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25: 1919-27, 2002.

Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonlymeasured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis15: 458-82, 1990.

Lu M, Wheeler MB, Leng XH, Boyd III AE. The role of the free cytosolic calcium level in beta-cellsignal transduction by gastric inhibitory polypeptide and glucagon-like peptide I (7-37).Endocrinology 132, 94-100, 1993.

Luckner M. Prufung von dragen. Gustav Fisher Verlag 1st edition. Jena, 214: 1966.

Madsbad S, McNair P, Christensen MS, Christiansen C, Faber OK, Binder C. Influence of smokingon insulin requirement and metbolic status in diabetes mellitus. Diabetes Care 3: 41-3, 1980.Maegawa H, Ide R, Hasegawa M. Thiazolidine derivatives ameliorate high glucose-induced insulinresistance via the normalization of protein tyrosine phosphatase activities. Journal of BiologicalChemistry 270: 7724, 1995.

Mak RH. Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolismin uremia. J Pediatr 129: 97-104, 1996.Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V. AGEs in patients with DN. N EnglJ Med 325: 836-42, 1991.Malhotra A, Sanghi V. Regulation of contractile proteins in diabetic heart. Cardiovascular Research34: 34−40, 1997.Malik AB, Abe T, Geha AS. Cardiac performance in ventricular hypertrophy induced by pressureand volume overloading. J Applied Physiol 37: 867-74, 1974.Malik, RA. Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibi-tors?Ann Med 32: 1-5, 2000.Malone JI, Schocken DD, Morrison AD, Gilbert-Barness E. Diabetic cardiomyopathy and carnitinedeficiency. Journal of Diabetes and Its Complications 13: 86−90, 1999.Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Annalsof Internal Medicine 130: 651-57, 1999.Manzella D, Barbieri M, Ragno E, Paolisso G. Chronic administration of pharmacologic doses ofvitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. AmericanJournal of Clinical Nutrition 73: 1052-57, 2001

References

257

Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G. The effects of testosterone treatmenton body composition and metabolism in middleaged obese men. Int J Obes Relat Metab Disord 16:991-7, 1992.

Martin SS, Haruta T, Morris AJ, Klippel A, Williams LT, Olefsky JM. ActivatedPhosphatidylinositol 3-Kinase Is Sufficient to Mediate Actin Rearrangement and GLUT4Translocation in 3T3-L1 Adipocytes. Journal of Biological Chemistry 271: 17605-8, 1996.

Martinez JA, Margareto J, Marti A, Milagro FI, Larrarte E, Moreno Aliaga MJ. Resistinoverexpression is induced by a beta3 adrenergic agonist in diet-related overweightness. Journal ofPhysiology and Biochemistry 57: 287-8, 2001.

Marwick TH. Diabetic heart disease. Heart 92. 296−300, 2006.Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, et al. ExperimentalNIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide.Diabetes 47: 224–9, 1998.

Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of longterm efficacy of captopril on preservation of kidney function in normotensive patients with insulindependent diabetes and microalbuminuria. BMJ 319: 24-5, 1999.

Matsuyama F. Composition for inhibiting increase of blood sugar level or lowering blood sugarlevel. United States Patent Application No. 09/730, 741; filed December 7, 2000.Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC. Structural-functionalrelationships in diabetic nephropathy. J Clin Invest 74: 1143-55, 1984.Mbanya JC, Sobngwi E, Mbanya DS, Nug KB. Left Ventricular mass and systolic function inAfrican diabetic patients: association with microalbuminuria. Diabetes Metabl 27: 378-82, 2001.MC study group. Predictors of the development of microalbuminuria in patients with Type 1 diabetesmellitus: a seven year prospective study. The Microalbuminuria Collaborative Study Group (MCstudy group). Diabet Med 16: 918-25, 1999.

McClain DA, Crook ED. Hexosamines and insulin resistance. Diabetes 45: 1003-9, 1996.McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzymeinhibitors prevent diabetes and cardiovascular disease. American Journal of Cardiology 91: 30H-7H,2003.

McGuire MC, Fields RM, Nyomba BL. Abnormal regulation of protein tyrosine phosphataseactivities in skeletal muscle of insulin-resistant humans. Diabetes 40: 939, 1991.Mei Q, Mundinger To, Lernmark A, Taborsky GJ. Early, selective and marked loss of sympatheticnerves from the islets inbreeded diabetic rats. Diabetes 51(10): 2997-3002, 2002.Meinhold JA, Maslowska-Wessel E, Bender R and Sawicki PT. Low prevalence of cardiacautonomic neuropathy in Type 1 diabetic patients without nephropathy. Diabet Med 18: 607-13,2001.Menne J, Park JK, Goerke A, Elger M, Boehne, Lindschau C, Bahlmann FH, Meier M, Leitges M,Haller H. Protein kinase C alpha activation is involved in the induction of tubular apoptosis underdiabetic condition. Kidney Blood Press Res 27: 267-423, 2004.

Merritt JC, Foody JM. Nonlipid cardiovascular risk factors. In B. P. Griffin, & E. J. Topol (Eds.),Manual of Cardiovascular Medicine. Philadelphia: Lippincott Williams & Wilkins. 2nd edition, pp.536–54, 2004.

Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC. Prognostic significance ofmicroalbuminuria in insulin-dependent diabetes mellitus: a twenty three year followup study. KidneyInt 41: 836-9, 1992.

Messereli FH, Sundgaad-Riise K, Reisin ED et al. Disparate cardiovascular effects of obesity andarterial hypertension. Am J Med 74: 808-12, 1983.Meyer C, Dostou JM, Gerich JE. Role of the human kidney in glucose counterregulation. Diabetes48: 943-8, 1999.

References

258

Miles P, Higo K, Romeo O, Lee M, Rafaat K, Olefsky J. Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. Diabetes 47: 395-400, 1998.Miles PD, Romeo OM, Higo K, Cohen A, Rafaat K, Olefsky JM. TNF-alpha-induced insulinresistance in vivo and its prevention by troglitazone. Diabetes 46: 1678-83, 1997.Miskulin DC, Meyer KB, Athienites NV, Martin AA, Terrin N, Marsh JV. Comorbidity and otherfactors associated with modality selection in incident dialysis patients: the CHOICE Study. Choicesfor Healthy Outcomes in Caring for ESRD. Am J Kidney Dis 39: 324-36, 2002.

Miura T, Ueda N, Yamada K, Fukushima M, Ishida T, Kaneko T, Matsuyama F, Seino Y.Antidiabetic effect of Corosolic acid in KK-AY Diabetic Mice. Biol. Pharm. Bull. 29(3): 585, 2006.Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H. Alteration inleft ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistantprediabetic stage of a type II diabetic rat model. Circulation 101(8): 899-907, 2000.

Mogensen CE, Chachati A, Christensen CK, Close CF, Deckert T, Hommel E. Microalbuminuria: anearly marker of renal involvement in diabetes. Uremia Invest 9: 85-95, 1985.Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease with emphasis onthe stage of incipient diabetic nephropathy. Diabetes 32 Suppl 2: 64-78, 1983.

Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW. Randomised controlled trialof dual blockade of RAS in patients with hypertension, microalbuminuria, and non-insulin dependentdiabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321: 1440-4, 2000.

Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H.Microalbuminuria and potential confounders. A review and some observations on variability ofurinary albumin excretion. Diabetes Care 18: 572-81, 1995.

Mogensen CE. Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. NEngl J Med, 311: 89-93, 1984.Mogensen CE. Long term antihypertensive treatment inhibiting progression of diabetic nephropathy.BMJ (Clin Res Ed 285: 685-8), 1982.Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onsetdiabetes. N Eng J Med 310: 356-60, 1984.Mokuda O, Sakamoty Y, Ikeda J, Mashiba H. Effects of anoxia and low free fatty acids inmyocardial energy metabolism in streptozotoem-diabetic rates. Ann Nutr Metab 34: 259-65, 1990.Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Diabeticnephropathy. Diabetes Care 26 Suppl 1: S94-8, 2003.Mollsten AV, Dahlquist GG, Stattin EL, Rudberg S. Higher intakes of fish protein are related to alower risk of microalbuminuria in young Swedish type 1 diabetic patients. Diabetes Care 24: 805-10,2001.Mommsen TP, Walsh PJ, Moon TW. Gluconeogenesis in hepatocytes and kidney of atlantic salmon.Molecular Pysiology 8: 89-100, 1985.Monti LD, Setola E, Fragasso G, Camisasca RP, Lucotti P, Galluccio E, Origgi A, Margonato A &Piatti P. Metabolic and endothelial effects of trimetazidine on forearm muscle in patients with type 2diabetes and ischemic cardiomyopathy. American Journal of Physiology Endocrinology andMetabolism 290: E54−E9, 2006.

Mooney RA, Senn J, Cameron S, Inamdar N, Boivin LM, Shang Y, Furlanetto RW. Suppressors ofcytokine signaling-1 and -6 associate with and inhibit the insulin receptor: a potential mechanism forcytokine-mediated insulin resistance. Journal of Biological Chemistry 276: 25889-93, 2001.

Morrish NJ, Wang SL, Stevens LK, Fuller JH and Keen H. Mortality and causes of death in theWHO Multinational Study of Vascular Disease in Diabetes, Diabetologia, 44 Suppl 2: S14-21, 2001.

References

259

Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goidstein BJ.Differential regulation of adiponectin secretion from cultured human omental and subcutaneousadipocytes: effects of insulin and rosiglitazone. Journal of Clinical Endocrinology and Metabolism87: 5662-7, 2002.

Moyers JS, Bilan PJ, Reynet C, Kahn CR. Over-expression of Rad inhibits glucose uptake incultured muscle and fat cells. Journal of Biological Chemistry 271: 23111-6, 1996.Mueckler M, Caruso C, Baldwin SA, Panico M, Blench I, Morris HR, Allard WJ, Lienhard GE,Lodish HF. Sequence and structure of a human glucose transporter. Science 229: 941-5, 1985.Mukarami C, Myoga, K, Kasai R, Ohtani K, Kurokawa, T, Ishibashi S, Dayrit F, Padolina Wg,Yamasaki K. Screening of plant constituents for effect on glucose transport activity in Ehrlich ascitestumor cells. Chemical and Phamaceutical Bulletin (Tokyo) 41: 2129-31, 1993.

Mukherjee PK. Quality control of herbal drugs an approach to evalution of botanicals. 1st edition,pp. 350, 2002.Mulec H, Blohme G, Grande B, Bjorck S. The effect of metabolic control on rate of decline in renalfunction in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol DialTransplant 13: 651-5, 1998.

Mulec H, Johnson SA, Bjorck S. Relation between serum cholesterol and diabetic nephropathy.Lancet 335: 1537-8, 1990.Murray I, Sniderman AD, Have1 PJ, Cianflone K. Acylation stimulating protein (ASP) deficiencyalters postprandial and adipose tissue metabolism in male mice. Journal of Biological Chemistry 274:36219-25, 1999.

Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM.Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistanceatherosclerosis study. Diabetes 47: 793-800, 1998.

Myrup B, Hansen P, Jensen T. effect of low dose heprin on urinary albumin excretion in insulindependent diabetes mellitus. Lancet 345: 421-2, 1995.Mysliwska J, Zorena K, Semetkowska-Jurkiewicz E, Rachon D, Suchanek H, Mysliwski A. Highlevels of circulating IL-10 in DN patients.Eur Cytokine Netw. 16(2): 117-22, 2005.Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression inhuman fat cells or skeletal muscle. Biochemical and Biophysical Research Communications 285:561-4, 2001.

Nakanishi K, Onuma S, Higa M, Nagai Y, Inokuchi T. The intrarenal blood flow distribution androle of NO in diabetic rats.Metabolism. 54(6): 788-92, 2005.

Nakano S, Kitazawa M, Ito T, Hatakeyama H, Nishizawa M, Nakagawa A, Kigoshi T & Uchida K.Insulin resistant state in type 2 diabetes is related to advanced autonomic neuropathy. Clinical andExperimental Hypertension 25: 155−167, 2003.

Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46-52, 1986.Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fastinghyperglycemia by exogenous glucagon-like peptide l(7-36) in type 2 (non-insulin-dependent)diabetes patients. Diabetologia 36: 741-4, 1993.

Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W. Normalization of fastingglycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients DiabetesMedicine 15: 937-45, 1998.

Nesto RW. Pharmacological treatment and prevention of heart failure in the diabetic patient.Reviews in Cardiovascular Medicine 5: 1−8, 2004.

References

260

Nevalainen P, Lahtela JT, Mustonen J, Pasternack A. The influence of peritoneal dialysis and the useof subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1diabetic patients. Nephrol Dial Transplant 12: 145-50, 1997.

Nevalainen PI, Kallio T, Lahtela JT, Mustonen J, Pasternack AI. High peritoneal permeabilitypredisposes to hepatic steatosis in diabetic continuous ambulatory peritoneal dialysis patientsreceiving intraperitoneal insulin. Perit Dial Int 20: 637-42, 2000.

Ng DP, Tai BC, Koh D, Tan KW, Chia KS. Angiotensin-I converting enzyme insertion/deletionpolymorphism and its association with DN: a meta analysis of studies reported between 1994 and2004 and comprising 14,727 subjects. Diabetologia 48(5): 1008-16, 2005.

Nielsen S, Jensen, MD. Relationship between urinary albumin excretion, body composition, andhyperinsulinemia in normotensive glucose tolerant adults. Diabetes Care 22: 1728-33, 1999.Nitenberg A, Valersi P, Sachs R. Impairment of coronary vascular reserve and Ach-induced coronaryvasodilatation in diabetic patients with angiographically normal coronary arteries and normal leftventricular systolic function. Diabetes 42: 1017-25, 1993.

Nordfeldt S, Samuelsson U. Serum ACE predicts severe hypoglycemia in children and adolescentswith type 1 diabetes. Diabetes Care 26: 274-8, 2003.Nordfors L, Lonnqvist F, Heimburger O, Danielsson A, Schalling M, Stenvinkel P. Low leptin geneexpression and hyperleptinemia in chronic renal failure. Kidney Int 54: 1267-75, 1998.Norris JM, Beaty B, Klingensmith G. Lack of association between early exposure to cow's milkprotein and b-cell autoimmunity: Diabetes autoimmunity study in the young (DAISY). Journal ofAmerican Medical Association 276: 609, 1996.

Nunoda S, Genda A, Sekiguchi M, Takeda R. Left ventricular endomyocardial biopsy findings inpatients with essential hypertension and hypertrophy Cardiomyopathy with special reference to theincidence of bizarre myocardial hypertrophy with disorganization and biopsy score. Heart vessels 1:170-5, 1985.

Nyberg G, Svensson M. Selection of uremic patients for kidney transplantation. Clin Transplant 15:263-8, 2001.Nyberg, G, Blohme, G and Norden, G. Impact of metabolic control in progression of clinical DN.Diabetologia 30: 82-6, 1987.Nyholm B, Walker M, Gravholt CH, Shearing PA, Sturis J, Alberti KG. Twenty four-hour insulinsecretion rates, circulating concentrations of fue1 substrates and gut incretin hormones in healthyoffspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations.Diabetologia 42: 1314-1323, 1999.

O’Hare JP, Roland JM, Walters G, Corall RJM. Impaired sodium retention in response to volumeexpansion induced by water immersion in insulin dependent diabetes mellitus. Diabetes Res 3: 213-215, 1986.

Oakley WG. Clinical manifestations and associations. In clinical diabetes and its biochemical basis,ed WG Oakley, DA Ryke, and KW Taylor, Blackweil, Oxford, pp 252-83, 1968.

Ogawa Y, Masuzaki H, Isse N, Okazaki T, Mori T, Nakao K. Molecular cloning of rat obese cDNAand augmented gene expression in genetically obese Zucker fatty (fa/fa) rats. Journal of ClinicalInvestigation 96: 1647-52, 1995.

Okada T, Kawano Y, Sakakibara T, Hazeki O, Ui M. Essential role of phosphatidylinositol 3-kinasein insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selectiveinhibitor wortmannin. Journal of Biological Chemistry 269: 3568, 1994.

Oldstone MBA. Prevention of type 1 diabetes in nonobese diabetes mice by virus infection. Science239: 500, 1988.

References

261

Oliver B, Daniel B, Portha B. Relation of insulin deficiency to impaired insulin action in NIDDMadult rat given streptozotocin as neonates. Diabetes 38: 610-7, 1989.Orchard TJ, Forrest KY, Kuller LH, and Becker DJ. Lipid and Blood pressure treatment goals fortype 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes ComplicationsStudy. Diabetes Care 24: 1053-9, 2001.

Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35: 701-711, 1992.Oskarsson PR, Lins PE, Backman L, Adamson UC. Continuous intraperitoneal insulin infusionpartly restores the glucagon response to hypoglycaemia in type 1 diabetic patients. Diabetes Metab26: 118-24, 2000.

Osterby R, Gundersen HJ, Horlyck A, Kroustrup JP, Nyberg G, Westberg G. Diabeticglomerulopathy. Structural characteristics of the early and advanced stages. Diabetes 32 Suppl 2: 79-82, 1983.Osterby R, Parving H, Nyberg G, Jorgensen H, Lokkegaard H, Svalander C. A strong correlationbetween GFR and filtration surface in DN. Diabetologia 31: 265-70, 1988.Osterby R. Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes,consequences, and prevention. Diabetologia 35: 803-12, 1992.Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P. An in vivo and in vitrostudy of the mechanism of prednisone-induced insulin resistance in healthy subjects. Journal ofClinical Investigation 72: 1814-20, 1983.

Paik SG, Fleischer N, Schin S. Insulin-dependant diabetes mellitus induced by subdiabetogenic dosesstreptozotocin: obligatory role of cell mediated autoimmune processes. Proceedings of NationalAcademy of Science USA, 77, 6129, 1980.

Pak CY, Eun HM, McArthur RG, Yoon JW. Association of cytomegalovirus infection withautoimmune type 1 diabetes. Lancet 2: 1, 1988.Palmer BF. Sexual dysfunction in uremia. J Am Soc Nephrol 10: 1381-8, 1999.Pamir N, Lynn FC, Buchan AM, Ehses J, Hinke SA, Pospisilik JA, Miyawaki K, Yamada Y, SeinoY, McIntosh CH, Pederson RA. Glucose-dependent insulinotropic polypeptide receptor null miceexhibit compensatory changes in the enteroinsular axis. Am J Physiol, Endocrinology andMetabolism 284: E931-E9, 2003.

Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C. Skeletal muscle triglyceridelevels are inversely related to insulin action. Diabetes 46: 983-8, 1997a.Pan XR, Li GW, Hn YH. Effects of exercise and diet in preventing NIDDM in people with impairedelucose tolerance: the Da Qing IGT and Diabetes study. Diabetes Care 20: 537, 1997.Parving HH, Hommel E, Damkjaer NM Giese J. Effect of captopril on blood pressure and kidneyfunction in normotensive insulin dependent diabetics with nephropathy. BMJ 299: 533-6, 1989.Parving HH, Kastrup H, Smidt UM, Andersen AR, Feldt-Rasmussen B, Christiansen JS. Impairedautoregulation of glomerular filtration rate in type 1 (insulin-dependent) diabetic patients withnephropathy. Diabetologia 27: 547-52, 1984.

Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect ofirbesartan on the development of DN in patients with type 2 diabetes. N Engl J Med 345: 870-8,2001.Parving HH, Oxenboll B, Svendsen PA, Christiansen JS, Andersen AR. Early detection of patients atrisk of developing DN. A longitudinal study of urinary albumin excretion. Acta Endocrinol(Copenh), 100: 550-5, 1982.

Parving, HH, Jacobsen, P, Tarnow, L, Rossing, P, Lecerf, L, Poirier, O, et al. Effect of deletionpolymorphism of ACE gene on progression of diabetic nephropathy during inhibition of ACE:observational follow up study. BMJ 313: 591-4, 1996.

References

262

Passadakis P, Thodis E, Vargemezis V, Oreopoulos D. Long term survival on peritoneal dialysis inESRD owing to diabetes. Adv Perit Dial 16: 59-66, 2000.Paternostro G, Pagano D, Gnecchi-Ruscone T, Bonser RS, Camici PG. Insulin resistance in patientswith cardiac hypertrophy. Cardiovascular Research, 2, 46−53, 1999.Paz-Guevara AT, Hsu TH and White P. Juvenile diabetes mellitus after forty years. Diabetes 24:559-65, 1975.Pedersen MM, Christiansen JS, Mogensen CE. Reduction of glomerular hyperfiltration innormoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition. Diabetes 40: 527-31,1991.Pedersen O, Schmitz O, Hjollund E, Richelsen B, Hansen HE. Postbinding defects of insulin actionin human adipocytes from uremic patients. Kidney Int 27: 780-4, 1985.Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B. Activity ofACE and risk of severe hypoglycaemia in type 1 diabetes mellitus. Lancet 357: 1248-53, 2001.Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucosetolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitorisoleucine thiazolidide. Diabetes 47: 1253-8, 1998.

Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction onthe progression of diabetic and nondiabetic renal diseases: a metaanalysis. Ann Intern Med 124: 627-32, 1996.

Pellegrino M, Christophe B, Rene G, Michele R, Michele M, Dominique H, Michela N, Gerard K.Experimental NIDDM: Development of a New Model in Adult Rats Administered Streptozotocinand Nicotinamide. Diabetes 47(2): 224-9, 1998.

Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta,TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysispatients. Kidney Int 45: 890-6, 1994.

Pessin JE, Thurmond DC, Elmendorf JS, Coker KJ, Okada S. Molecular basis of insulin-stimulatedGLUT4 vesicle trafficking location. Journal of Biological Chemistry 274: 2593-6, 1999.Peter P, Martin U, Sharma A, Dunne F. Effect of treatment with nebivolol on parameters of oxidativestress in type 2 diabetics with mild to moderate hypertension. Journal of Clinical Pharmacy andTherapeutics 31: 153-9, 2006.

Pettitt DJ, Aleck KA, Baird HR, Carraher MJ, Bennet PH, Knowler WC. Congenital susceptibility toNIDDM: the role of intrauterine environment. Diabetes 37: 622, 1988.Pettitt DJ, Forman MR, Hanson RL, Knowler LC, Bennt PH. Breastfeeding and incidence of non-insulin dependant diabetes mellitus in Pima Indians. Lancet 350: 166, 1997.Pfab T,Thone-Reineke C, Lange I, Richter CM, Yanagisawa M, Hocher B. Diabetic ETB receptordeficient rats develop severe hypertension and pronounced renal pathology. Kidney Blood Press Res27: 267-423, 2004.

Pfeffer SR. Transport-vesicle targeting: tethers before SNARES. Nature Cell Biology l(1): 17-22,1999.Polese A, De Cesare N, Montorsi P. Upward shift of the lower range of coronary flow autoregulationin hypertensive patients with hypertrophy of left ventricle. Circulation 83: 845-53, 1991.

Polonsky KS, Given BD, Hirsch I, Tilil H, Sharpiro ET, Beebe C. Abnormal patterns of insulinsecretion in non-insulin dependent diabetes mellitus. . N Engl J Med 318: 1231-39, 1988.Portha B, Levancher AE, Picolon L, Rosselin G. Diabetogenic effect of streptozotocin in the ratduring the prenatal period. Diabetes 23: 883-95, 1979a.Portha B, Picolon L, Rosselin G. Chemical diabetes in the adult rat as the spontaneous evolution ofneonatal diabetes. Diabetologia 17: 371-7, 1979.

References

263

Portha B, Serradas P, Bailbe D, Suzuki K, Goto Y, Giroix MH. Beta-cell insensitivity to glucose inthe GK rat, a spontaneous nonobese model for type 2 diabetes. Diabetes 40: 486-91, 1991.Poulsen P, Kyvik KO, Vaag A, Beck-Nielson H. Heritability of type I1 (non-insulin dependant)diabetes mellitus and abnormal glucose tolerance: a population based twin study. Daibetologia 42:139, 1999.

Poulsen PL, Hansen KW, Mogensen CE. Ambulatory blood pressure in the transition from normo tomicroalbuminuria. A longitudinal study in IDDM patients. Diabetes 43: 1248-53, 1994.Prem AR, Punekar SV, Kalpana M, Kelkar AR, Acharya VN. Male reproductive function inuraemia: efficacy of haemodialysis and renal transplantation. Br J Urol 78: 635-8, 1996.Prince PSM, Menon VP, Pari L. Hypoglycemic activity of Syzigium cuimini seeds: effect on lipidperoxidation in alloxan diabetic rats. Journal of Ethnopharmacology 61: 1-7, 1998.Pugliese A, Gianani R, Morornisato R. HLA-DQB1*0602 is associated with dominant protectionfrom diabetes even among islet cell antibody-positive first degree relatives of patients with IDDM.Diabetes 44: 608, 1995.

Qi D, Pulinilkunnil T, An D, Ghosh S, Abrahani A, Pospisilik JA, Brownsey R, Wambolt R, AllardM, Brian Rodrigues B. Single-dose dexamethasone induces whole-body insulin resistance and altersboth cardiac fatty acid and carbohydrate metabolism. Diabetes 53: 1790-7, 2004.

Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms ofadministration. J Am Soc Nephrol 13 Suppl 1: S92-6, 2002.Quinn M, Angelico MC, Warram JH, Krolewski AS. Familial factors determine the development ofDN in patients with IDDM. Diabetologia 39: 940-5, 1996.Quisumbing E. Medicinal Plants of the Philippines. Katha Publishing, Quezon City, pp. 640-2, 1978.Rabin DU, Pleasic SM, Palmer-crocker R, Shapiro JA. Cloning and expression of IDDM-specifichuman autoantigens. Diabetes 41: 183, 1992.Rabinovitch A, Saurez-Pinzon W, El-Sheik A, Sorenson O, Powere RF. Cytotoxic gene expressionin pancreatic islet infiltrating leukocytes of BB rats: expression of Thl cytokines correlates with betacell destructive insulitis and IDDM. Diabetes 45 (6), 749, 1996.

Rabinovitch A. Irnmunoregulatory and cytokine imbalances in the pathogenesis of IDDM:therapeutic intervention by immunostimulation? Diabetes 43: 613, 1994.Rabkin R, Simon NM, Steiner S, Colwell JA. Effect of renal disease on renal uptake and excretion ofinsulin in man. N Engl J Med 282: 182-7, 1970.Rachman J, Barrow BA, Levy JC, Turner RC. Near-nonnalisation of diurnal glucose concentrationsby continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.Diabetologia 40: 205-11, 1997.

Radrigues B, Cam, McNeil JH. Metabolic Disturbances in Diabetic cardiomyopathy. Mol CellBiochem 180: 53-7, 1998.Raev DC. Which left ventricular function is impaired earlier in the evolution of diabeticcardiomyopathy? An echocardiographic study of young Type-1 diabetic patients.Diabetes Care 17:633-9, 1994.

Raju J, Gupta D, Rao AR. Trigonellafoenum graecunm (fenugreek) seed powder improves glucosehomeostasis in alloxan diabetic rat tissues by reversing the altered glycolytic, gluconeogenic andlipogenic enzymes. Molecular and Cellular Biochemistry 224: 45-51, 2001.

Rakietan N, Rakietan ML, Nadkarni MV. Studies on diabetogenic action of streptozotocin. CancerChemotherapy 29: 91-8, 1963.Randle P, Garland P, Hales C, Newsholme E. The glucose fatty acid cycle: its role in insulinsensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785-9, 1963.Rasch R. Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment.Kidney size and glomerular volume. Diabetologia 16: 125-8, 1979.

References

264

Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O. Tissue specificdysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86: 1418-21, 2001.Rathi SS, Grover JK, Vats V. Anti-hyperglyceinic effects of Momordica charantia and Mucunapruriens in experimental diabetes and their effect on key metabolic enzymes involved incarbohydrate metabolism. Phytotherapy Research 16: 236-43, 2002.

Rave K, Heise T, Pfutzner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy onpharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. DiabetesCare 24: 886-90, 2001.

Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuatedecline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus.A randomized, controlled trial. Ann Intern Med 128: 982-8, 1998.

Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. ArchIntern Med 158: 998-1004, 1998.

Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long term stabilizing effect of ACEinhibition on plasma creatinine and on proteinuria in nor motensive type II diabetic patients [seecomments]. Ann Intern Med 118: 577-81, 1993.

Ray BS, Pazianos AG, Greenberg E, Peretz WL, McLean JM. Pituitary ablation for diabeticretinopathy. I. Results of hypophysectomy. (A ten year evaluation). Jama 203: 79-84, 1968.

Rayfield E, Kelly K, Yoon JW. Rubella virus-induced diabetes in hamsters. Diabetes 35: 1276, 1986.Rea S, James DE: Moving GLUT4. the biogenesis and trafficking of GLUT4 storage vesicles.Diabetes 46: 1667-77, 1997.Reddy KS, Stablein D, Taranto S, Stratta RJ, Johnston TD, Waid TH. Long term survival followingsimultaneous kidney pancreas transplantation versus kidney transplantation alone in patients withtype 1 diabetes mellitus and renal failure. Am J Kidney Dis 41: 464-70, 2003.

Regan TJ, Wu CF, Yeh CK, Oldewurtel HA, Haider B. Myocardial composition and function indiabetes. The effects of chronic insulin use. Circulation Research 49: 1268−77, 1981.Reichard P, Nilsson BY, Rosenqvist U. The effect of long term intensified insulin treatment on thedevelopment of microvascular complications of diabetes mellitus. N Engl J Med 329: 304-9, 1993.Reichard P. Are there any glycemic thresholds for the serious microvascular diabetic complications?J Diabetes Complications 9: 25-30, 1995.Reichel H, Deibert B, Schmidt-Gayk H, Ritz, E. Calcium metabolism in early chronic renal failure:implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 6: 162-9, 1991.Remuzzi G, Bertani T. is glomerulosclerosis a consequence of altered glomerular permeability tomacromolecules. Kidney Int 38: 384-94, 1990.Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-56,1998.Ren J, Dominguez LJ, Sowers JR, Davidoff A. Troglitazone attenuates high glucose-inducedabnormalities in relaxation and intracellular calcium in rat ventricular myocytes. Diabetes 45: 1822-25, 1996.

Ren J, Sowers JR, Walsh MF, Brown RA. Reduced contractile response to insulin and IGF-1 inventricular myocytes from genetically obese Zucker rats. Am J Physiol. 279: H1708-H14, 2000.Ren JM, Li PM, Zhang RW. Transgenic mice deficient in the LAR protein tyrosine phosphataseexhibit profound defects in glucose homeostasis. Diabetes 47: 493, 1998.Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM. Influence ofdiabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant15: 89-94, 2001.

References

265

Ribon V, Printen JA, Hoffman NG, Kay BK, Saltiel AR. A novel, multifunctional c-Cbl bindingprotein in insulin receptor signaling in 3T3-L1 adipocytes. Molecular and Cellular Biology 18: 872-9,1998.Riddick F, Reisler D, Kipnis D. The sugar transport system in striated muscle. Diabetes 11: 171-8,1962.Rigalleau V, Blanchetier V, Combe C, Guillot C, Deleris G, Aubertin J. A low protein diet improvesinsulin sensitivity of endogenous glucose production in predialytic uremic patients. Am J Clin Nutr65: 1512-6, 1997.

Ritz E, Ogata H, Orth SR. Smoking: a factor promoting onset and progression of DN. DiabetesMetab 26 Suppl 4: 54-63, 2000.

Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341: 1127-33,1999.

Ritz E. Managing anaemia and diabetes: a future challenge for nephrologists.Nephrol Dial TransplantSuppl 6: vi21-vi5, 2005.

Riva E, Andreoni G, Bianchi R, Latini R, Luvarà G, Jeremic G, Traquandi C, Tuccinardi L. Changesin diastolic function and collagen content in normotensives and hypertensive rats with long termstreptozotocin-induced diabetes. Pharmacol Res. 37(3): 233-40, 1998.

Robinson T. The Organic Constituents of Higher Plants, their Chemistry and Interrelationships.Minneapalis 15 Minn., Burgers publishing company, pp. 290, 1964.Robinson T. The Organic Constituents of Higher Plants, their Chemistry and Interrelationships.Minneapalis 15 Minn., Burgers publishing company, pp.64, 1964.Roden M, Price TB, Perseghin G, Petersen KF, Rothrnan DL, Cline GW. Mechanism of free fattyacid-induced insulin resistance in humans. Journal of Clinical Investigation 97: 2859-65, 1996.Rodrigues B, Goyal RK, McNeill JH. Effects of hydralazine on STZ-induced diabetic rats-prevention of hyperlipidemia and improvement in cardiac function. Journal of Pharmacology andExperimental Therapeutics 237: 299-307, 1986.

Rodrigues B, Cam MC & McNeill JH. Metabolic disturbances in diabetic cardiomyopathy.Molecular and Cellular Biochemistry 180: 53−7, 1998.Rooney DP, Neely RD, Cullen C, Ennis CN, Sheridan B, Atkinson AB. The effect of cortisol onglucose/glucose-6-phosphate cycle activity and insulin action. Journal of Clinical Endocrinology andMetabolism 77(5): 1180-3, 1993.

Rosen OM. After insulin binds. Science 237: (4821), 1452-8, 1987.Ross SA. Gulve EA, Wang M. Chemistry and biochemistry of type 2 diabetes. Chemical Reviews104: 1255-82, 2004.Rossert JA, McClellan WM, Roger SD, Verbeelen DL, Horl WH. Contribution of anaemia toprogression of renal disease: a debate. Nephrol Dial Transplant 17 Suppl 1: 60-6, 2002.Rossetti L, Hawkins M, Chen W, Gindi J, Barzilai N. In vivo glucosamine infusion induces insulinresistance in normoglycemic but not in hyperglycemic conscious rats. Journal of ClinicalInvestigation 96: 132-140, 1995.

Rossetti L, Stenbit AE, Chen W. Peripheral but not hepatic insulin resistance in mice with onedisrupted allele of the glucose transporter type 4 (GLUT4) gene. Journal of Clinical Investigation100: 1831-9, 1997.

Rossing P, Hommel E, Smidt UM, Parving HH. Impact of arterial blood pressure and albuminuria onthe progression of DN in IDDM patients. Diabetes 42: 715-9, 1993.Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effecton diminishing the progression of human DN during antihypertensive treatment. Diabetologia 37:511-6, 1994.

References

266

Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependentdiabetes: 10 year observational follow up study. BMJ 313: 779-84, 1996.

Rossing P, Tarnow L, Nielsen FS, Hansen BV, Brenner BM, Parving HH. Low birth weight. A riskfactor for development of DN? Diabetes 44: 1405-7, 1995.Rossini AA, Greiner DL, Friedman HP: Immnuopathogenesis of diabetes mellitus. Diabetes Review1: 43, 1993.Roussos L, Ekstrom U, Ehle PN, Oqvist B, Floren CH. Apolipoprotein E polymorphism in 385patients on renal replacement therapy in Sweden. Scand J Urol Nephrol 38 (6):504-10, 2004.Rubenstein AH, Mako ME, Horwitz DL. Insulin and the kidney. Nephron 15: 306-26, 1975.Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW & Grishman A. New type ofcardiomyopathy associated with diabetic glomerulosclerosis. American Journal of Cardiology 30:595−602, 1972.

Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW and Grishman A. New type ofCardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30: 595-602, 1972.Rudberg S, Osterby R, Bangstad HJ, Dahlquist G, Persson B. Effect of ACE-I or beta blocker onglomerular structural changes in young microalbuminuric patients with Type I (insulin-dependent)diabetes mellitus. Diabetologia 42: 589-95, 1999.

Rudberg S, Persson B and Dahlquist, G. Increased glomerular filtration rate as a predictor of diabeticnephropathy: an 8-year prospective study. Kidney Int 41: 822-8, 1992.Rudberg S, Persson B, Dahlquist G. Increased GFR as a predictor of DN an 8-year prospective study.Kidney Int 41: 822-8, 1992.Rudberg S, Stattin EL, Dahlquist G. Familial and perinatal risk factors for micro andmacroalbuminuria in young IDDM patients. Diabetes 47: 1121-6, 1998.Rudnicki PM, Molsted-Pedersen L. Effect of 1,25-dihydroxycholecalciferol on glucose metabolismin gestational diabetes mellitus. Diabetologia 40: 40-4, 1997.Rudofsky G Jr, Schlimme M, Schlotterer A, von Eynatten M, Reismann P, Tafel J, Grafe I, MorcosM, Nawroth P, Bierhaus A, Hamann A. No association of the 94T/G polymorphism in theadiponectin gene with diabetic complications.Diabetes Obes Metab 7(4): 455-9, 2005.

Russell III RR, Yin R, Caplan MJ et al. Additive effects of hyperinsulinemia and ischemia onmyocardial GLUT 1 and GLUT 4 translocation in vivo. Circulation 2180-6, 1998.Rutter MK, Parise H, Benjamin EJ, Levy D, Larson, MG, Meigs JB, Nesto RW, Wilson PW &Vasan RS. Impact of glucose intolerance and insulin resistance on cardiac structure and function:sexrelated differences in the Framingham Heart Study. Circulation 107: 448−54, 2003.

Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M. J., Cosentino, F.,Jonsson, B., Laakso, M., Malmberg, K., Priori, S., Ostergren, J., Tuomilehto, J., Thrainsdottir, I.,Vanhorebeek, I., Stramba-Badiale, M., Lindgren, P., Qiao, Q., Priori, S. G., Blanc, J. J., Budaj, A.,Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J.,Osterspey, A., Tamargo, J., Zamorano, J. L., Deckers, J.W., Bertrand, M., Charbonnel, B., Erdmann,E., Ferrannini, E., Flyvbjerg, A., Gohlke, H., Juanatey, J. R., Graham, I., Monteiro, P. F., Parhofer,K., Pyorala, K., Raz, I., Schernthaner, G., Volpe, M., Wood, D. Task Force on Diabetes andCardiovascular Diseases of the European Society of Cardiology (ESC), & European Association forthe Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases:executive summary. European Heart Journal, 28: 88−136, 2007.

Saad MJ, Folli F, Araki E, Hashimoto N, Csermely P, Kahn CR. Regulation of insulin receptor,insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-F442A adipocytes. Effects ofdifferentiation, insulin, and dexamethasone. Molecular Endocrinology 8: 545-57, 1994.

References

267

Sadlier DM, Henger A, Brunner B, Nitsche A, Bleich, Hensey C, Schmid H, Doran P, Boucherot A,O’Meara YM, Cohen CD, Groene HJ, Schlondorff D, Brady HR, Kretzler M. Genome wideexpression profiling identifies activation of Wnt signaling and novel TGF-b pathway members inhuman DN. Kidney Blood Press Res 27: 267-423, 2004.

Sakoda H, Ogihara T, Anai M, Funaki M, Inukai K, Katagiri H. Dexamethasone induced insulinresistance in 3T3-Ll adipocytes is due to inhibition of glucose transport rather than insulin signaltransduction. Diabetes 49: 1700-8, 2000.

Salmeron J, Ascherio A, Rimm EB. Dietary fiber, glycemic load and risk of NIDDM in men.Diabetes Care 20: 545, 1997.Samuelsson O, Lee DM, Attman PO, Knight-Gibson C, Mullen JK, Larsson R. The plasma levels ofhomocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression.Nephron 82: 306-11, 1999.

Santamaria P, Utsugi T, Park B-J, Averill N, Kawazu S, Yoon JW. Beta cell cytotoxic CD8+ T cellsfrom non-obese diabetic mouse use highly homologous T-cell receptor chain CDR3 sequences.Journal of Immunology 154: 2494, 1995.

Saraheimo M, Forsblom C, Fagerudd J, Teppo AM, Pettersson-Fernholm K, Frystyk J, Flyvbjerg A,Groop PH. Serum adiponectin is increased in type 1 diabetic patients with nephropathy.DiabetesCare. 28(6): 1410-4, 2005.

Satoh MS, Lindahl T. Role of poly (ADP-ribose) formation in DNA repair. Nature 356: 356-8, 1992.

Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV. Resistin/Fizz3expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action inhumans. Diabetes 50: 2199-202, 2001.

Savage MP, Krolewski AS, Kenien GG, Lebeis MP, Christlieb AR, Lewis SM. Acute myocardialinfarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. AmJ Cardiol, 62: 665-9, 1988.

Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associatedwith progression of DN. Diabetes Care 17: 126-31, 1994.Schaffer SW, Warner BA, Wilson GL. Effects of chronic glipizide treatment on the NIDD heart.Horm Metab Res 25: 348–52, 1993.Schein PS, O'Comell MJ, Bkom J. Clinical anti-tumour activity and toxicity of streptozotocin (NSC-85998). Cancer 34: 993-1000, 1974.Scheinaman J, Steffed MW, Brown DM, Mauer SM. The immunohistopathology of glomerularantigen III. Increased mesangial actomyosin in experimental diabetes in the rat. Diabetes 27: 632-7,1978.Schena FP, Gesualdo L. Pathogenetic mechanisms of DN. J Am Soc Nephrol Suppl 1: S30-3, 2005.

Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q,produced exclusively in adipocytes. Journal of Biological Chemistry 270: 26746-9, 1995.Schleicher ED, Weigert C. Role of the hexosamine biosynthetic pathway in DN. Kidney Int Suppl77: S13-8, 2000.Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 22: 72-82,1993.Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chroniccongestive heart failure. Clinical Science 99: 27−35, 2000.Schmitz O, Alberti KG, Christensen NJ, Hasling C, Hjollund E, Beck-Nielsen H. Aspects of glucosehomeostasis in uremia as assessed by the hyperinsulinemic euglycemic clamp technique. Metabolism34: 465-73, 1985.

Schmitz O. Absence of diurnal plasma prolactin rhythm in diabetic and non-diabetic uraemicpatients. Acta Endocrinol (Copenh) 105: 173-8, 1984.

References

268

Schmitz O. Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependentdiabetic subjects. Diabetes 34: 1152-9, 1985.Schmitz O. Peripheral and hepatic resistance to insulin and hepatic resistance to glucagon in uraemicsubjects. Studies at physiologic and supraphysiologic hormone levels. Acta Endocrinol (Copenh)118: 125-34, 1988.

Schnedl WJ, Ferber S, Johnson JH, Newgard CB. STZ transport and cytotoxiciiy. Specificenhancement in GLUT2-expressing cells. Diabetes 43: 1326-33, 1994.Schulze I, Gazith J, Gooding R. Hexokinase, Methods in Enzymology 9, W.A. Wood, AcademicPress, NY, p376, 1966.Schwannwell CM, Schneppenheim M, Perings S et al. Left ventricular diastolic dysfunction as anearly manifestation of diabetic cardiomyopathy. Cardiology 98: 33-9, 2002.Scivittaro, V, Ganz, MB and Weiss, MF. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 278: F676-83, 2000.Seidner G, Alvarez MG, Yeh JI. GLUT-1 deficiency syndrome caused by haploinsufficiency of theblood brain barrier hexose carrier. Nature Genetics 18: 188-91, 1998.Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris, Furlanetto RW, Mooney RA. Suppressor ofCytokine Signaling-3 (SOCS-3), a Potential Mediator of Interleukin-6-dependent Insulin Resistancein Hepatocytes Journal Of Biological Chemistry 278: 13740-6, 2003.

Serreze DV, Chapman HD, Varnum DS. Initiation of autoimmune diabetes in NOD/Lt mice is MHCclass I dependant. Journal of Immunology 158: 3978, 1997.Sevak AR, Goyal RK. Effect of chronic treatment with lisinopril on cardiovascular complications instreptozotocin-induced diabetic and DOCA hypertensive rats. Pharma. Res. 34 (5-6): 201, 1996.Shafrir E. Animal models of non insulin dependent diabetes. Diab Metab Rev 8: 179–208, 1992.Shafrir E. Diabetes in animals: Contribution to the understanding of diabetes by study of itsetiopathology in animal models. In: Porte D, Sherwin RS, Baron A, editors. Diabetes mellitus.NewYork: McGraw-Hill p. 231-55, 2003.

Sharma D, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-b by anti- TGF-b antibody attenuateskidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabeticmice. Diabetes 45(4): 522-30, 1996.

Shehadeh A, Regan TJ. Cardiac consequences of diabetes mellitus. Clin Cardiol 18: 301-5, 1995.Shepherd PR, Abel ED, Kahn BB. Glucose transporters and pathophysiologic states. In: DiabetesMellitus, A Fundamental and Clinical Text, Le Roith D, Taylor SI, Olefsky JM, (Eds.) 2nd Edition,Lippincott-Williams & Wilkins, Philadelphia, USA, pp. 627-41, 2000.

Shimomura H, Spiro RG. Studies on macromolecular components of human GBM and alterations indiabetes. Decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 36: 374-81, 1987.Shimotomai T, Kakei M, Narita T, Koshimura J, Hosoba M, Kato M, Komatsuda A. Enhancedurinary adiponectin excretion in IgA-nephropathy patients with proteinuria.Ren Fail. 27(3): 323-8,2005.

Shoelson SE, White MF, Kahn CR. Tryptic activation of the insulin receptor. Journal of BiologicalChemistry 263: 4852-60, 1988.Shrinivasan K, Viswanad B, Asrat L, Kaul C, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening.Pharmacological Research 52: 313-20, 2005.

Sim SK. Medicinal Plant alkaloid. University of Toronto Press: 9, 1969.Simbulan-Rosenthal CM. The expression of poly (ADP-ribose) polymerase during differentiation-linked DNA replication reveals that it is a component of the multiprotein DNA replication complex.Biochemistry 35: 11622- 33, 1996.

References

269

Simes JJH, Tracey JG, Webb LJ and Dunstan WJ. An Australian Phytochemical survey - Saponins inEastern Australian Flowering Plants. Australia common wealth scientific Industrial Researchorganization Bulletin: 281: 31, 1959.

Simon K, Throne-Reineke C, Richter CM, Godes M, Thormahlen D, Hocher B. Inhibition of bothneutral-endopeptidase and endothelin-converting-enzyme by SLV306 reduces proteinuria andurinary albumin excretion in diabetic rats. J Pharmacol 44: 576-9, 2004.

Singh R, Alavi N, Singh AK, Leehey DJ. Role of AT II in glucose induced inhibition of mesangialmatrix degradation. Diabetes 48: 2066-73, 1999.SNBHW. The Swedish National board of Health and Welfare. National Guidelines for Diabetes Careand Treatment 67-8, 1999.Song HX, Gong J, Chen WC. Effect of triptolide on urinary MCP-1 in patients with DN. ZhongguoZhong Xi Yi Jie He Za Zhi 25(5): 416-8, 2005.Sowers JR, Epstein M, Frohlich ED. Diabetes, Hypertension and Cardiovascular disease An Update.Hypertension 37: 1053-68, 2001.Sowers JR, Epstein M. Diabetes mellitus and associate hypertension, vascular disease, andnephropathy: an update. Hypertension 26(pt 1): 869-79, 1995.

Spallone V, Gambardella S, Maiello MR, Barini A, Frontoni S and Menzinger G. Relationshipbetween autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensiveIDDM patients. Diabetes Care 17: 578-84, 1994.

Spiegelman BM. PPAR-gamma : Adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507–14, 1998.Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Adiponectin andprotection against type 2 diabetes mellitus. Lancet 361: 226-8, 2003.Srinivasan K, Patole PS, Kaul CL, Ramarao P. Reversal of glucose intolerance by pioglitazone inhigh-fat diet fed rats. Methods Find Exp Clin Pharmacol 26: 327–33, 2004.Standaert ML, Bandyopadhyay G, Perez L, Price D, Galloway L, Poklepovic A, Sajan MP, Cenni V,Sim A, Moscat J, Toker A, Farese RV. Insulin Activates Protein Kinases C-x and C-l by anAutophosphorylation-dependent Mechanism and Stimulates Their Translocation to GLUT4 Vesiclesand Other Membrane Fractions in Rat Adipocytes. Joumal of Biological Chemistry 274: 25308-16,1999.

Standaert ML, Galloway L, Karnam P, Bandyopadhyay G, Moscat J, Farese RV. Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in ratadipocytes: potential role in glucose transport. Journal of Biological Chemistry 272: 30075-82, 1997.

Standaert ML, Ortmeyer HK, Sajan MP, Kanoh Y, Bandyopadhyay G, Hansen BC, Farese RV.Skeletal Muscle Insulin Resistance in Obesity-Associated Type 2 Diabetes in Monkeys Is Linked toa Defect in Insulin Activation of Protein Kinase C-x/l/i. Diabetes 51: 2936-43, 2002.

Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS,Metcalf D, Nicola NA, Hilton DJ. A family of cytokine-inducible inhibitors of signaling. Nature 387:917-21, 1997.

Steffses MW, Bilous RW, Sutherland DER, Mauer SM. Cell and matrix components of theglomerular messangium in type I diabetes mellitus. Diabetes 41: 679-84, 1992.Steffses MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism forloss of kidney function in diabetic patients. Diabetes 38: 1077-81, 1989.Stenbit AE, Tsao TS, Li J. GLUT4 heterozygous knockout mice develop muscle insulin resistanceand diabetes. Nature Medicine 3: 1096- 1101, 1997.Stenvinkel P, Alvestrand A. Inflammation in ESRD: sources, consequences, and therapy. Semin Dial15: 329-37, 2002.

References

270

Stenvinkel P, Andersson P, Wang T, Lindholm B, Bergstrom J, Palmblad J. Do ACE-I suppressTNF-a production in advanced chronic renal failure? J Intern Med 246: 503-7, 1999.Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM. The hormone resistin linksobesity to diabetes. Nature 409: 307-12, 2001.Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY. 4 family of tissue-specificresistin-like molecules. Proceedings of National Academy of Science USA 98: 502-6, 2001a.Storlien LH, James DE, Burleigh KM, Chisholm DJ, Kraegen EW. Fat feeding causes widespread invivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J Physiol(Endocrinology and Metabolism) 14: E576-E83, 1986.

Storm TL, Sorensen OH, Lund B, Christiansen, JS, Andersen AR, Lumholtz IB. Vitamin Dmetabolism in insulin-dependent diabetes mellitus. Metab Bone Dis Relat Res 5: 107-10, 1983.Strauer BE, Motz W, Vogt M, Schwartzkopff B. Impaired coronary flow reserve in NIDDM: apossible role for diabetic cardiopathy in humans. Diabetes 46(Suppl 2): S119−S24, 1997.Suenaga K, Yoon JW. Association of beta cell-specific expression of endogenous retrovirus with thedevelopment of insulitis and diabetes in NOD mice. Diabetes 37: 1722, 1988.Sundkvist G, Lilja B. Autonomic neuropathy predicts deterioration in glomerular filtration rate inpatients with IDDM. Diabetes Care 16: 773-9, 1993.Sunni S, Bishop SP, Kent SP, Geer JC. Diabetic Cardiomyopathy. A morphologic study ofintramyocardial arteries. Arch Pathol Lab Med 110: 375-81, 1986.Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-induced type II diabetes inC57BL/6J mice. Diabetes 37: 1163-1 167, 1988.Suto J, Matsuura S, Yamanaka H, Sekikawa K. Quantitative trait loci that regulate plasma lipidconcentration in hereditary obese KK and KK-Ay mice. Biochimica Biophysics Acta 1453: 385-95,1999.

Suzuki K, Kono T. Evidence that insulin causes translocation of glucose transport activity to theplasma membrane from an intracellular storage site. Proceedings of National Academy Science USA77: 2542-45, 1980.

Suzuki Y, Unno T, Ushitani M, Hayashi K, Kakuda T. Antiobesity activity of extracts fromLagerstroemia speciosa L. leaves on female KK-Ay mice. J Nutr Sci Vitaminol. Dec; 45(6): 791-5,1999

Swanston-Flatt SK, Day C, Bailey CJ, Flatt PR. Traditional plant treatments for diabetes: studies innormal and streptozotocin diabetic mice. Diabetologia 33: 462-4, 1990.Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth, OA,Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Lévy S, Linde C, Lopez-Sendon JL,Nieminen MS, Piérard L & Remme WJ. Task Force for the Diagnosis and Treatment of ChronicHeart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment ofchronic heart failure: executive summary. European Heart Journal 26: 1115−40, 2005.

Sweeney G, Somwar R, Ramlal T, Volchuk A, Ueyanla A, Klip A. An inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transportertranslocation in 3T3-L1 adipocytes and L6 myotubes. Journal of Biological Chemistry 274: 15,10071-8, 1999.

Sykiotis GP, Papavassiliou AG. Minireview: Serine Phosphorylation of Insulin Receptor Subs- trate-1: A Novel Target for the Reversal of Insulin Resistance. Molecular Endocrinology 15: 1864-9,2001.

Tahiliani AG, Vadlamudi, RV, Mcneill JH. Prevention and reversal of altered myocardial function indiabetic rats by insulin treatment. Can J Physiol Pharmacol. 61: 516-23, 1983.Tajima M, Yazawa T, Hagiwara K. Diabetes mellitus in cattle infected with bovine viral diarrheamucosal disease virus. Journal of Veterinary Medical Association 34: 616, 1992.

References

271

Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, Tegayuchi Y, Ueki K.Kaburagi Y, Sato S. Insulin resistance and growth retardation in mice lacking insulin receptorsubstrate-1. Nature 372: 182-186, 1994.

Tamsma JT, Van den Born J, Bruijun J. Expression of glomerular extracellular matrix components inhuman DN: decrease of heparan sulfate in GBM. Diabetologia 37: 313-20, 1994.Tanti J, Gremeaux T, Grillo S. Over-expression of a constitutively active form ofphosphatidylinositol 3-kinase is sufficient to promote Glut 4 translocation in adipocytes Journal ofBiological Chemistry 271: 25227-32, 1996.

Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA,Clark FT, Deeds J. Identification and expression cloning of leptin receptor, OB-R. Cell 83: 1263-1271, 1995.

Tay YC, Wang Y, Kairaitis L, Rangan GK, Zhang C, Harris DC. Can murine DN be separated fromsuperimposed acute renal failure? Kidney Int 68(1): 391-8, 2005.Taylor AV, Wise PH. Vitamin D replacement in Asians with diabetes may increase insulinresistance. Postgrad Med J 74: 365-6, 1998.

Taylor CA, 3rd, Abdel-Rahman E, Zimmerman SW, Johnson CA. Clinical pharmacokinetics duringcontinuous ambulatory peritoneal dialysis. Clin Pharmacokinet 31: 293-308, 1996.Taylor RJ, Bennet PH, LeGonidec G. The prevalence of diabetes mellitus in traditional-livingPolynesian population: the Wallis island survey. Diabetes care 6: 334, 1983.Terrettaz J, Jeanrenaud B. In vivo hepatic and peripheral insulin resistance in genetically obese(falfa) rats. Endocrinology 112: 1346-51, 1983.Tesfamariam B, Jakubowski JA, Cohen RA. Contraction of diabetic rabbit aorta caused byendothelium derived PGH2-TxA2. Am J Physiol 257: 1327-33, 1989.The Ayurvedic Pharmacopoeia of India. Government of India Part I, Vol. 1, 1st edition, Ministry ofHealth and Family Welfare, Department of Health 143, 1986.

The EUCLID Study Group. Randomised placebo controlled trial of lisinopril in normotensivepatients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLIDStudy Group. Lancet 349: 1787-92, 1997.

Thomas MC, Burns WC, Cooper ME. Tubular changes in early DN. Adv Chronic Kidney Dis 12(2):177-86, 2005.Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, SigurdssonG & Rydén L. The association between glucose abnormalities and heart failure in the populationbased Reykjavík Study. Diabetes Care 28: 612−6, 2005.

Toft I, Bonaa KH, Eikrem J, Bendiksen AL, Iversen H, Jenssen T. Microalbuminuria in hypertensionis not a determinant of insulin resistance. Kidney Int 61: 1445-52, 2002.Toker A, Meyer M, Reddy KK, Falck JR, Aneja R, Aneja S, Parra A, Burns DJ, Ballas LM, CantleyLC. Activation of protein kinase C family members by the novel polyphosphoinositides PtdIns-3,4-P2 and Ptdhs-3,4,5-P3. Journal of Biological Chemistry 269: 32358-67, 1994.

Tolins J, Schultz P, Raij L, Brown D, Mauer S. abnormal renal hemodynamic response to reducedrenal perfusion pressure in diabetic rats: role of NO. Am J Physiol 265: F886-F95, 1993.Tong P, Thomas T, Berrish T, Humphriss D, Barriocanal L, Stewart M. Cell membrane dynamicsand insulin resistance in non-insulin-dependent diabetes mellitus. Lancet 345: 357-8, 1995.Toniolo A, Onodera T, Jordon G: Virus-induced diabetes mellitus. Glucose abnormalities producedin mice by all six members of the Coxsackie B virus group. Diabetes 31: 496, 1982.Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P. Reduction of albumin excretion ratein normotensive microalbuminuric type 2 diabetic patients during long term simvastatin treatment.Diabetes Care 20: 1891-5, 1997.

References

272

Tonshoff B, Blum WF, Mehls O. IGF and IGF binding proteins in children with chronic renalfailure. Prog Growth Factor Res 6: 481-91, 1995.Trease GE and Evance WC. Tests for carbohydrates. Trease and Evans Pharmacognosy. HarcourtBrace and Company Asia Pvt. Ltd. Singapore. 15th edition, pp. 193-227, 2002.Tseng CC, Zhang XY, Wolfe MM. Effect of GIP and GLP-1 antagonists on insulin release in the rat.American Journal of Physiology 276: E1049-E54, 1999.Tsuru M, Katagiri H, Asano T, Yamada T, Ohno S, Ogihara T, Oka Y. Role of PKC isoforms inglucose transport in 3T3-L1 adipocytes: insignificance of atypical PKC. American Journal ofPhysiology, Endocrinology and Metabolism 283: E338-E45, 2002.

Tyden G, Tollemar J, Bolinder J. Combined pancreas and kidney transplantation improves survivalin patients with end stage DN. Clin Transplant 14: 505-8, 2000.Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (socs-1) and socs-3 cause insulinresistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins bydiscrete mechanisms. Molecular and Cellular Biology 24: 5436-46, 2004.

Ukkola O. Resistin - a mediator of obesity-associated insulin resistance or an innocent bystander?European Journal of Endocrinology 147: 571-4, 2002.UKPDS 33. Intensive blood glucose control with sulphonylureas or insulin compared withconventional treatment and risk of complications in patients with type 2 diabetes. UK ProspectiveDiabetes Study (UKPDS) Group. Lancet 352: 837-5, 1998.

UKPDS 38. Tight blood pressure control and risk of macrovascular and microvascular complicationsin type 2 diabetes. UK Prospective Diabetes Study Group [see comments] [published erratumappears in BMJ 1999 Jan 2;318(7175):29]. BMJ 317: 703-13, 1998.

UKPDS 38. Tight blood pressure control and risk of macrovascular and microvascular complicationsin type 2 diabetes: UKPDS 38. BMJ 317: 703-13, 1998a.Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, CoussensL, Liao YiC,Tsubokawa My Mason Ai Seeburg PH, Grunfeld C, Rosen OM, Ramachandran J. Human insulin,receptor and its relationship to the tyrosine kinase family of oacogenes. Nature 313:756-61, 1985.

Umrani DN, Goyal RK. Beneficial effects of fenoldopam treatment on renal functions instreptozotocin induced diabetic rats. Clin. Exper. Hypertension. 24(3):207-19, 2002.Upton R, Widdowson P, Ishii S, Tanaka H, Williams G. Improved metabolic status and insulinsensitivity in obese fatty (falfa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with thethiazolidinedione, MCC-555. British Journal of Pharmacology 125: 1708-14, 1998.

Uribarri J, Oh MS, Carroll HJ. Hyperkalemia in diabetes mellitus. J Diabet Complications 4(1): 3-7,1990.

Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulinresistance in mice lacking TNF-alpha function. Nature 389: 610-4, 1997.

Vadlamudi RVSV, Rodgers RL, McNeill JH. The effect of chronic alloxan and streptozotocininduced diabetes on isolated rat heart performance. Can J Physiol Pharmacol 60:902-11, 1982.Van Heerebeek L, Somsen A, Paulus WJ. The failing diabetic heart: focus on diastolic leftventricular dysfunction. Curr Diab Rep. 9(1): 79-86, 2009.Van Hoeven KH & Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic,and hypertensivediabetic heart disease. Circulation 82: 848−55, 1990.

Vareesangthip K, Tong P, Wilkinson R, Thomas TH. Insulin resistance in adult polycystic kidneydisease. Kidney Int 52: 503-8, 1997.Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGEprotein cross links. Expert Opin Investig Drugs 10: 1977-87, 2001.Vasylyeva TL, Chen X, Ferry RJ Jr. ICF binding protein-3 mediates cytokine-induced mesangial cellapoptosis. Growth Horm IGF Res 15(3): 207-14, 2005.

References

273

Vats V, Yadav SP, Grover JK. Ethanolic extract of Ocimum sanctum leaves partially attenuatesstreptozotocin-induced alterations in glycogen content and carbohydrate metabolism in rats. Journalof Ethnopharmacology 90: 155-60, 2004.

Veldhuis JD, Wilkowski MJ, Zwart AD, Urban RJ, Lizarralde G, Iranmanesh A. Evidence forattenuation of hypothalamic gonadotropin-releasing hormone (GnRH) impulse strength withpreservation of GnRH pulse frequency in men with chronic renal failure. J Clin Endocrinol Metab76: 648-54, 1993.

Velloso LA, Eizirik DL, Karlsson FA. Absence of antibodies against glutamic acid decarboxylase(GAD) in non-obese diabetic (NOD) mouse and low expression of the enzyme in mouse islets.Clinical and Experimental Immunology 96: 129, 1994.

Vered A, Battler A, Segal P et al. Exercise induced left ventricular dysfunction in young men withasymptomatic diabetes mellitus (Diabetic cardiomyopathy). Am J Cardiol 54: 633-7, 1984.

Vervoort G, Veldman B, Berden JH, Smits P, Wetzels JF. Glomerular hyperfiltration in type 1diabetes mellitus results from primary changes in proximal tubular sodium handling without changesin volume expansion. Eur J Clin Invest 35(5): 330-6, 2005.

Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Makmud U, Keen H. Microalbuminuria as apredictor of clinical nephropathy in insulin dependent diabetes mellitus. Lancet 1: 1430-32, 1982.Viberti GC, Keen H, Wisemen MJ. Raised arterial pressure in parents of proteinuric insulindependent diabetes mellitus. BMJ 295: 515-7, 1985.

Vita G, Savica V, Milone S, Trusso A, Bellinghieri G, Messina C. Uremic autonomic neuropathy:recovery following bicarbonate hemodialysis. Clin Nephrol 45: 56-60, 1996.Vlachojannis GJ, Scholz-Pedretti K, Fierlbeck W, Geiger H, Pfeilschifter J, Kaszkin M. Enhancedexpression of group IIA secreted phospholipase A2 by elevated glucose levels in cytokine-stimulatedrat mesangial cells and in kidneys of diabetic rats. Clin Nephrol 63(5): 356-67, 2005.

Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation: role in the pathogenesis ofdiabetic complications. Clin Chem, 32: B37-41, 1986.Vlassara H, Brownlee M, Manogue KR, Dinarello C, Pasagian A. Cachectin/TNF and IL-1 inducedby glucose modified proteins: role in normal tissue remodeling. Science 240: 1546-8, 1988.

Vlassara H, Striker LJ, Teichberg S, Fuh H, Li Y, Steffes M. AGEs induced glomerulosclerosis andalbuminuria in normal rats. Proc Natl Acad Sci 91(11): 704-11, 1994.Von Bibra H, Hansen A, Dounis V, Bystedt, T, Malmberg K, Rydén L. Augmented metaboliccontrol improves myocardial diastolic function and perfusion in patients with non-insulin dependentdiabetes. Heart 90: 1483−4, 2004.

Von Harsdorf R, Li PF & Dietz R. Signaling pathways in reactive oxygen species-inducedcardiomyocyte apoptosis. Circulation 99: 2934−41, 1999.Waddell ID, Zomerschoe AG, Voice MW, Burchell A. Cloning and expression of a hepaticmicrosomal glucose transport protein. Comparison with liver plasma-membrane glucose-transportprotein GLUT 2. Biochemical Journal 286: 173-7, 1992.

Wallace EZ, Rosman P, Toshav N, Sacerdote A, Balthazar A. Pituitary adrenocortical function inchronic renal failure: studies of episodic secretion of cortisol and dexamethasone suppressibility. JClin Endocrinol Metab 50: 46-51, 1980.

Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO. Intracerebroventricular interleukin-6treatment decreases body fat in rats. Biochemical and Biophysical Research Communications 293:560-5, 2002a.

Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO.Interleukin-6-deficient mice develop mature-onset obesity. Nature Medicine 8: 75-9, 2002.

References

274

Wang Q, Somwar R, Bilan PJ. Protein kinase B/Akt participates in GLUT4 translocation by insulinin L6 myoblasts. Molecular and Cellular Biology 19: 4008-18, 1999.

Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB. Inhibition of the Jak/STAT signaling pathwayprevents the high glucose induced increase in TGF-β and fibronectin synthesis in mesangial cells.Diabetes 51: 3505-9, 2002.

Wangler RD, Peter KG, Tomanek RJ. Effect of duration and severity of arterial hypertension andcardiac hypertrophy on coronary vasodilator reserve. Circulation Research 51: 10-8, 1982.

Ward DT, Hamilton K, Burnand R, Smith CP, Tomlinson DR, Riccardi D. Altered expression of irontransport proteins in streptozotocin-induced diabetic rat kidney. Biochim Biophys Acta 1740(1): 79-84, 2005.

Ward KP, Galloway WH, Auchterlonie IA. Congenital cytomegalovirus infection and diabetes.Lancet 1: 497, 1979.

Watson RT, Shigematsu S, Chiang S-H, Mora S, Kanzaki M, Macara IG, Saltiel AR, Pessin JE.Lipid raft microdomain compartmentalization of TC10 is required for insulin signaling and GLUT4translocation. Journal of Cell Biology 154: 829, 2001.

Watts GF & Marwick TH. Ventricular dysfunction in early diabetic heart disease: detection,mechanisms and significance. Clinical Science (Lond) 105: 537-40, 2003.

Weber G, Lea MA, Fisher EA. Regulatory pattern of liver carbohydrate metabolizing enzymes;insulin as an inducer of key glycolytic enzymes. Enzymology Biology Clinics (Basel) 7: 11-24,1966.Weide LG, Lacy PE. Low-dose streptozotocin-induced autoimmune diabetes in islet transplantationmodel. Diabetes 40: 1157, 1991.

Weidmann P, Boehlen LM, de Courten M. Pathogenesis and treatment of hypertension associatedwith diabetes mellitus: American Heart Journal 125: 1498-1513, 1993.

Weir GC, Clore EE, Zma-Chinsky CJ, Bonnier-Weir S. Islet secretion in new experimental modelfor non-insulin dependent diabetes. Diabetes and Metabolism Reviews 30: 590-5, 1981.

Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA.Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance andhyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 86: 1930-5, 2001.

White MF, Kahn CR. The cascade of autophosphorylation in the b-subunit of the insulin receptor.Journal of Cell Biochemistry 39: 429, 1989.

White MF, Shoelson SE, Keutmann H, Kahn CR. A cascade of tyrosine autophosphorylation in thep-subunit activates the insulin receptor. Journal of Biological Chemistry 263: 2969-80, 1988.

Wiese RJ, Mastick CC, Lazar DF, Saltiel AR. Activation of mitogen-activated protein kinase andphosphatidylinositol 3'-kinase is not sufficient for the hormonal stimulation of glucose uptake,lipogenesis, or glycogen synthesis in 3T3-L1 adipocytes. Journal of Biological Chemistry 270: 3442-6, 1995.

Wikdahl AM, Granbom L, Stegmayr BG. No increased risk for peritonitis by insulin injected intoperitoneal dialysis solution bag through Coloplast. Anna J 24: 401-6; discussion 407-8, 1997.

Wild S, Roglic G, Green A, Sicree R & King H. Global prevalence of diabetes: estimates for the year2000 and projections for 2030. Diabetes Care 27: 1047−53, 2004.

Wilkes B. Reduced glomerular AT II receptor density in diabetes mellitus in the rat: time course andmechanisms. Endocrinology 120: 1291-8, 1987.

William J, Hogan D, Batlle D. Predicting the development of DN and its progression. Adv ChronicKidney Dis 12(2): 202-11, 2005.

References

275

Williamson JR, Kilo C. Capillary basement membrane thickening and diabetic microangiopathy.Diabetes. 25: 925-7, 1976.

Wilson JA and Merill HB. Analysis of Leather and Material used in making it, 1st ed. New York, TheMcgraw Hill Book Co. Inc., pp.290-3, 1931.

Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S;Shulman GI, Bonner-Weir S, White MF. Disruption of IRS-2 causes type 2 diabetes in mice. Nature391: 900-4, 1998.

Wittmann I, Molnar GA, Degrell P, Wagner Z, Tamasko M, Laczy B, Brasnyo P, Wagner L, NagyJ.Prevention and treatment of DN. Diabetes Res Clin Pract. 68 Suppl 1: S36-42, 2005.Wold LE, Ceylan-Isik AF & Ren J. Oxidative stress and stress signaling: menace of diabeticcardiomyopathy. Acta Pharmacologica Sinica 26: 908−17, 2005.Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN. High glucose induced prolilferation inmesangial cells is decreased by autocrine TGF-b. Kidney Int 42: 747-56, 1992.Wolfe RA, Ashby VB, Milford EL, Ojo AO Ettenger RE, Agodoa LY. Comparison of mortality inall patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a firstcadaveric transplant. N Engl J Med 341: 1725-30, 1999.

Wong CY, O' Moore-Sullivan T, Leano R, Byrne N, Beller E & Marwick TH. Alterations of leftventricular myocardial characteristics associated with obesity. Circulation 10: 81−7, 2004.Worm D, Vinten J, Staehr P, Henriksen JE, Handberg A, Beck-Nielson H. Altered basal and insulin-stimulated phosphotyrosine phosphatase (PTPase) activity in skeletal muscle fractions from NIDDMpatients compared with control subjects. Diabetologia 39: 1208, 1996.

Xia P, Inoguchi T, Kern TS et al.Characterisation of the mechanism for the chronic activation ofdiacyl-glycerol protein kinase C pathway in diabetes and hyperglactosemia. Diabetes 43: 1122-9,1994.

Xu Y, Osborne BW, Stanton RC. Diabetes Causes Inhibition of Glucose-6-PhosphateDehydrogenase via Activation of Protein Kinase A which Contributes to Oxidative Stress in RatKidney Cortex.Am J Physiol Renal Physiol 289: F1040-7, 2005.

Yadav S, Vats V, Dhunnoo Y, Grover JK. Hypoglycemic and antihyperglycemic activity of Murrayakoenigii leaves in diabetic rats. Journal of Ethnopharmacology 82: 111-6, 2002.Yamagami K, Hosoi M, Yamamoto T, Fukumoto M, Yamakita T, Miyamoto M, Yoshioka K, IshiiT, Sato T, Tanaka S, Fujii S. Coronary arterial calcification is associated with albuminuria in type 2diabetic patient. Diabetes Obes Metab 7(4): 390-6, 2005.

Yamagishi S, Takeuchi M, Inoue H.Olmesartan medoxomil, a newly developed AT II type 1receptor antagonist, protects against renal damage in AGEs-injected rats. Drugs Exp Clin Res 31(2):45-51, 2005.

Yamamoto H, Uchigata Y, Okamoto H. Streptozotocin and alloxan induce DNA strand breaks andpoly (ADP-ribose) synthetase in pancreatic islets. Nature 294: 284-6, 1981.Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of TGF-β is elevated inhuman and experimental DN. Proc Natl Acad Sci 90: 1814-8, 1993.Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K. The fat derived hormoneadiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-6, 2001.

Yang J, Clarke JF, Ester CJ, Young PW, Kasuga M, Holman GD. Phosphatidylinositol 3-kinase actsat an intracellular membrane site to enhance GLUT4 exocytosis in 3T3-L1 cells. BiochemicalJournal 313: 125-31, 1996.

Yildiz A, Sever MS, Demirel S, Akkaya V, Turk S, Turkmen A. Improvement of uremic autonomicdysfunction after renal transplantation: a heart rate variability study. Nephron 80: 57-60, 1998.

References

276

Yip J, Mattock M, Sethi M, Morocutti A, Viberti G. Insulin resistance in family members of insulin-dependent diabetic patients with microalbuminuria [letter]. Lancet 341: 369-70, 1993.Yki-Jarvinen H, Koivisto VA. Insulin sensitivity in newly diagnosed type 1 diabetics afterketoacidosis and after three months of insulin therapy. J Clin Endocrinol Metab 59: 371-8, 1984.Yki-Jarvinen H, Taskinen MR, Kiviluoto T, Hilden H, Helve E, Koivisto VA. Site of insulinresistance in type 1 diabetes: insulin-mediated glucose disposal in vivo in relation to insulin bindingand action in adipocytes in vitro. J Clin Endocrinol Metab 59: 1183-92, 1984.

Yokota T, Utsunomiya K, Murkawa Y, Kurata H, Tajima N. mechanism of preventive effect ofHMG-CoA reductase inhibitor on DN. Kidney Int 56(Sul 71): S178-S81, 1999.Yoon JW, Hee-Sook J. Role of viruses in the pathogenesis of type 1 diabetes mellitus. In: DiabetesMellitus, A Fundamental and Clinical Text, LeRoith D, Taylor SI, Olefsky JM: eds. 2nd Edition,Lippincott Williams & Wilkins, Philadelphia, 419-30, 2000.

Yoon JW. Pathogenesis of IDDM. Environmental factors. In: Pickup I, Williams G, eds. Textbook ofdiabetes, London: Blackwell scientific publications, 14.1, 1997.Yoshida H, Kuriyama S, Atsumi Y. Angiotensin I converting enzyme gene polymorphism in non-insulin diabetes mellitus. Kidney Int 50: 657-64, 1996.Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M. Glucose-loweringand insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabeticfatty zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48: 1026-34, 1999.

Yu ZW, BurCn J, Enerback S, Nilsson E, Samuelsson L, Eriksson JW. Insulin can enhance GLUT4gene expression in 3T3-F442A cells and this effect is mimicked by vanadate but counteracted byCAMP and high glucose - potential implications for insulin resistance. Biochimica Biophysica Acta1535: 174-85, 2001.

Zabalgoitia M, Ismaeil MF, Anderson L & Maklady FA. Prevalence of diastolic dysfunction innormotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. AmericanJournal of Cardiology 87: 320-3, 2001.

Zarich SW, Nesto RW. Diabetic Cardiomyopathy. Am Heart J 118: 1000-12, 1989.

Zhang PL, MacKenzie HS, Troy JL, Brenner BM. Effects of ANP antagonist on glomerularhyperfiltration in diabetic rats. J Am Soc Nephrol 4: 1564-70, 1994.Zhang PL, Yahya TM, Prichard JW, Shaw JH 4th, Hartle JE, Lin F, Schwartzman MS. Case report:IgM type of membranous glomerulopathy in a diabetic patient.Ann Clin Lab Sci 35(2): 184-8, 2005.

Zhang SL, Filep JG, Hohman TC, Tang SS, Ingelfinger JR, Chan JS. Molecular mechanisms ofglucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int 55: 454-64, 1999.Zhejiang Da Xue Xue Bao Yi Xue Ban. Expression of a-smooth muscle actin in kidney of diabeticrats. 34(2): 152-6, 2005.Zheng FM, Ren YZ, Zhao TF. Preliminary clinical observation on effect of soduim ferulate intreating DN. Zhongguo Zhong Xi Yi Jie He Za Zhi 25(5): 419-21, 2005.Zhi YF, Johannes BP, Marwick JH. Diabetic Cardiomyopathy: Evidences , mechanism andtherapeutic implications. Endocrine Reviews 25(4): 543-67, 2004.Ziegler MG, Kennedy B, Morrissey E, O'Connor DT. Norepinephrine clearance, chromogranin Aand dopamine beta hydroxylase in renal failure. Kidney Int 37: 1357-62, 1990.Zierath JR, Galuska 3, Nolte LA, Thorne A, Kristensen JS, W'allberg-Henriksson H. Effects ofglycaemia on glucose transport in isolated skeletal muscle from patients with NIDDM: in vitroreversal of muscular insulin resistance. Diabetologia 37: 270-7, 1994.

Zierath JR, He L, Guma A, Wahlstrom EO, Klip A, Wallberg-Henriksson E. Insulin action onglucose transport and plasma membrane GLUT4 content in skeletal muscle from patients withNIDDM. Diabetologia 39: 1180-89, 1996.

References

277

Zimme P. Globalization, coca-colonization and the chronic disease epidemic: can the doomsdayscenario be averted? Journal of Internal Medicine 247: 301-10, 2000.Zimmet PZ, McCarty DJ, de Courten MP. The global epidemiology of non-insulin dependentdiabetes mellitus and the metabolic syndrome. Journal of Diabetes and Complications 11: 60-8,1997.Zimmet PZ: KelIy West Lecture 1991. Challenges in diabetes epidemiology: From West to rest.Diabetes care 15: 232, 1992.Ziyadeh FN, Goldfarb S, Kern EFO. Diabetic nephropathy: metabolic and biochemical mechanisms.In: The kidney in diabetes. (Eds) Brenner BM, Stein JH. Churchill-Livingstone, New York, 87-113,1989.Ziyadeh FN. Mediators of hyperglycemia and the pathogenesis of matrix accumulation in diabeticrenal disease. Miner Electrolyte Metab 21: 292-302, 1995.Ziyadeh FN. The extracellular matrix in DN. Am J Kidney Dis 22: 736-44, 1993.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S. Adiponectin, metabolicrisk factors, and cardiovascular events among patients with ESRD. J Am Soc Nephrol 13: 134-41,2002.